The discovery of insulin in 1921 was a milestone event that introduced the possibility of systematic research of insulin action (Fig. 1). Frederick Sanger (1918-2013) sequenced bovine insulin in 1955, identifying its exact amino-acids composition, and was awarded with the Nobel Prize for Chemistry in 1958. In 1965, a large team in the People’s Republic of China successfully synthesized the crystalline bovine insulin with full biological activity, immunogenicity and chemical property for the first time in the world. Subsequently, human insulin was produced using recombinant DNA methods and genetic modification of bacteria. Insulin therapy and understanding its mechanisms of action become important later research targets. Insulin is a peptide hormone that is produced and released by islets pancreatic β cells, that finely regulates the glucose uptake from blood into liver, fat, and skeletal muscle cells. Insulin also promotes several other cellular processes, including regulation of glycogen synthesis, lipid metabolism, DNA synthesis, gene transcription, amino acid transport, protein synthesis and degradation.

Under normal physiological conditions, increased plasma glucose levels lead to increased insulin secretion and circulating insulin levels, thereby stimulating glucose transfer into peripheral tissues and inhibiting hepatic gluconeogenesis. Individuals with deficient insulin-stimulated glucose uptake into muscle and adipocytes tissues, in addition to impaired insulin suppression of hepatic glucose output, are described as having ‘insulin resistance’ (IR). Several diseases are clinically associated with IR includes obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome, cardiovascular disease, MAFLD, PCOS, and cancer. Thus, there is an urgent need to identify the mechanisms of IR and effective interventions for treating these metabolic diseases. A relatively safe and well accepted approach in the prevention and treatment of IR is via lifestyle interventions. Nutritional intervention is an important first step that emphasizes a low-calorie and low-fat diet that stimulates excessive insulin demands. In addition, increased physical activity is recommended to help increase energy expenditures and improve muscle insulin sensitivity, this two approach represent the fundamental treatment for IR. The second step is the use of pharmacological medications, including metformin, oral sulphphonylureas, oral sodium-glucose cotransporter 2 (SGLT2) inhibitors, oral dipeptidyl peptidase 4 (DPP-4) inhibitors, oral α-Glucosidase, injectable glucagon-like peptide 1 (GLP1) receptor agonists, or injectable insulin.

In this review, the mechanism of insulin action and IR are first described to promote the development of new therapeutic strategies. Further, the direct and indirect effects of insulin on target tissues are discussed to better understand the pivotal role of tissue crosstalk in systemic insulin action. Lastly, diseases associated with IR are discussed and summarized. Many methods and multiple surrogate markers have been developed to calculate the IR. We then summarize the current measurements and potential biomarkers of IR to facilitate the clinical diagnosis. Finally, we provide the general approaches including lifestyle intervention, specific pharmacologic interventions and clinical trials to reduce IR. 

THE INSULIN SIGNALING AND IR
Insulin is an endocrine peptide hormone with 51 amino acids and composed of an α and a β chain linked together as a dimer by two
disulfide bridges \(^{18}\) along with a third intrachain disulfide bridge in the \(\alpha\) chain. \(^{19,20}\) Insulin is released by pancreatic beta cells and is essential for glucose and lipid homeostasis. \(^{21}\) Insulin binds the insulin receptor (INSR) on the plasma membrane of target cells, leading to the recruitment/phosphorylation of downstream proteins, that primarily including insulin receptor substrate (IRS), PI3-kinase (PI3K), and AKT isoforms, that are largely conserved among insulin target tissues and that initiate the insulin response. \(^{22,23}\)

The pathway diversification of insulin signaling downstream targets of Akt activation leads to different distal signaling in target tissues response to insulin (Fig. 2). (1) AKT substrates include the inactive glycogen synthase kinase 3 (GSK3) and active protein phosphatase 1 (PP1) that promote glycogen synthesis. \(^{24-26}\) In addition, the transcription factor forkhead box O1 (FOXO1) is phosphorylated by AKT and is transported from the nucleus, thereby disabling its transcription factor activity and inhibiting gluconeogenesis. \(^{27,28}\) (2) Tuberous sclerosis complex 1/2 (TSC1/2) and proline-rich Akt substrate 40 (PRAS40) are inhibitors of mTORC1, thereby inducing protein synthesis and adipogenesis. \(^{29,30}\) (3) The upregulation of sterol regulatory element binding protein 1c (SREBP-1c), de-phosphorylation of ATP citrate lyase (ACLY) lead to fatty acid synthesis. \(^{31}\) (4) Phosphodiesterase 3B (PDE3B) and the abhydrolase domain containing 15 (ABHD15) protein are involved in suppression of lipogenesis in adipocytes by inhibiting adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL). \(^{34,35}\)

Accumulation of reports have demonstrated that IR is a complex metabolic disorder with integrated pathophysiology. The exact causes of IR has not been fully determined. \(^{36-38}\) but ongoing research seeks to better understand how IR develops. Here, we focus on the underlying mechanism of IR including direct defective of insulin signaling, epidemiological factors, interorgan metabolic crosstalk, metabolic mediators, genetic mutation, epigenetic dysregulation, non-coding RNAs, and gut microbiota dysbiosis.

The direct defective of insulin signaling

As has been mentioned, the proper modulators acting on different steps of the signaling pathway ensure appropriate biological responses to insulin in different tissues. Thus, the diverse defect in signal transduction contributes to IR.

Proximal insulin receptor signaling and IR. Insulin exerts its biological effects by binding to its cell-surface receptors, thereby activating specific adapter proteins, such as the insulin receptor substrate (IRS) proteins (principally IRS1 and IRS2), Src-homology 2 (SH2) and protein-tyrosine phosphatase 1B (PTP1B), eventually promoting downstream insulin signaling involving glucose homeostasis. \(^{39}\) Thus, changes in insulin receptor expression, ligand binding, phosphorylation states, and/or kinase activity accounts for many IR phenotypes.

Most individuals that are obese or diabetic exhibit decreased surface INSR content and INSR kinase (IRK) activity. \(^{40}\) Defective IRK activity is also implicated by decreased IRS1 tyrosine phosphorylation which is consistently observed in insulin-resistant skeletal muscles. \(^{45}\) In addition, the specific knockout or ablation of INSR in livers prevents insulin suppression of hepatic glucose production (HGP), \(^{42,43}\) suggesting a direct role for INSR in hepatic IR. Second, decreased expression or serine phosphorylation of IRS proteins can reduce their binding to PI3K, thereby down-regulating PI3K activation and inducing apparent IR. Third, homozygous mice of IRS1 or IRS2 gene leading to peripheral IR and diabetes, and impaired insulin secretion through restrained PI3K/AKT signal transduction. \(^{45}\) Thus, pharmacological inhibitors, blocking antibodies and knockdown of PI3K abolishes the insulin stimulation of glucose transport, GLUT4 translocation and DNA synthesis. \(^{47-49}\) Additionally, deletion of Pik3r1 and Pik3r2 that encode PI3K subunit isoforms in skeletal muscle inhibits insulin-stimulated glucose transport. \(^{50}\) Similarly, interfering Akt mutant suppresses insulin-stimulated GLUT4 translocation, \(^{51}\) and inhibition of AKT expression, or impairment in AKT Ser473 phosphorylation are certainly detected in both muscle and liver IR. \(^{52,53}\) Further, there are three known isoforms of Akt1/2/3 in insulin sensitive tissues, the present study showed that the Akt2 and Akt3 defects impaired insulin-stimulated glucose transport in IR. \(^{54}\) In addition, elevated plasma nonesterified fatty acid (NEFA) levels impaired the insulin-induced increase in IRS-1-associated PI3K activity, but no defect in Akt phosphorylation was observed. \(^{55}\) Together, the combined actions of various disorders in the proximal signaling components leads to impaired glucose metabolism and IR, and a major challenge remains for understanding IR mechanisms regarding how to distinguish the causes from insulin effects or primary defects from their consequences.

Distal downstream signaling and IR. It is generally accepted that diverse downstream targets of Akt activation lead to different distal signaling in target tissues response to insulin. As mentioned above, there are more than 100 Akt substrates mainly including GLUT4, FOXO1, GSK3, mTORC1, SREBP-1c, TSC1/2, PRAS40, ABHD15, PDE3B. \(^{56}\) Among them, GLUT4 is the best characterized and mediates glucose uptake in skeletal muscle and white adipose cells after insulin stimulation. \(^{57,58}\) Impaired translocation of intracellular GSV (GLUT4 storage vesicles) caused decreased insulin-stimulated glucose uptake which are associated with IR in muscle and adipose tissues. \(^{59}\) This proved that heterozygous deletion of Glut4 mice reduce glucose uptake and develop
metabolic disease in adipocytes. Similarly, defection of insulin-stimulated GLUT4 translocation to the cell surface occurs in skeletal muscle in various IR mice models and humans with T2DM. In addition, loss of Tbc1d4 in mice that phosphorylated by Akt leads to the attenuation of downstream target activation of Rab-GTPase proteins associated with GLUT4 vesicles, and completely abolishes insulin-stimulated adipocyte glucose uptake. Mice homozygous for the physiologically important AKT substrate TBC1D4 Thr 649 knock-in exhibit impaired insulin-stimulated myocellular GLUT4 translocation and induction of glucose intolerance. In summary, continued discovery of novel AKT substrates involved in GLUT4 translocation indicates that many but not all of the same effectors are involved in the glucose uptake of different tissues, and further studies should be conducted to identify the molecular mediators in all phases of insulin-stimulated glucose uptake.

Epidemiology studies of IR

**Sex difference.** Different investigations have indicated that premenopausal women exhibit many less metabolic disorders than men, including lower incidence of IR, although this effect diminishes severely when women reach the postmenopausal situation. Specifically, female sex hormones including estradiol (e.g., 17β-oestradiol) protect female proopiomelanocortin (POMC) neurons from IR by enhancing POMC neuronal excitability and coupling insulin receptors to transient receptor potential (TRPC) channel activation. Comitantly, clinical and experimental observations have revealed that endogenous estrogens can protect against IR primarily through ERα activation in multiple tissues, including in the brain, liver, skeletal muscle, and adipose tissue, in addition to pancreatic β cells. Further, female hormone estrogens are determinants that mediate body adiposity levels and body fat distribution in addition to glucose metabolism and insulin sensitivity. Specifically, insulin sensitivity and capacities for insulin responses in women is significantly higher than men. Women younger than 51 had a significantly lower fasting glucose and triglyceride concentration compared with men. Furthermore, sex differences are associated with genetic polymorphisms in the development of IR and diabetes. Male homozygous for the polymorphism of PP1R3A gene that involved in glycogen synthase activity are significantly younger at diagnosis than female. The difference in regard to visceral, hepatic adiposity, hypoadiponectinemia, the insulin-sensitizing hormone-adiponectin, resting energy expenditure, lipid metabolism may also contribute to higher IR in male compared with female. Thus, additional studies are required to understand mechanisms underlying sex differences and IR development.

**Ethnicity difference.** T2DM is anticipated to impact nearly 600 million people globally by 2035, much of the investigations have recognized that the prevalence of T2DM are affected by different race/ethnicity, partly because of the differences in insulin sensitivity which affects plasma triglyceride levels. For example, Singapore Adults Metabolism Study (SAMS) performed a sub-group analysis and observed that Chinese and Malays exhibit greater insulin-sensitivity compared with Asian Indians among lean and young Singaporean males, the previous reports was further confirmed that the prevalence of T2DM in Chinese (9.7%) and Malays (16.6%) are lower than Asian Indians (17.2%). In the United Kingdom. South Asian children exhibit greater IR compared with white European children, while girls are more insulin resistant than boys, with sex and ethnicity differences related to insulin sensitivity and body composition. In addition, individuals of Aboriginal or South Asian descent (among Aboriginal, Chinese, and Indian populations) that also exhibit increased levels of body fat and visceral fat deposition appear to have a greater propensity for IR and type 2 diabetes. These interesting findings force us to reconsider the effect of the ethnic
differences in IR, which is important to reduce the morbidity and mortality related to diabetes mellitus and metabolic syndrome.

Modifiable lifestyle factors. Despite the above objective factors, some modifiable lifestyle factors including diet, exercise, smoking, sleep and stress are also considered to contribute to IR. For instance, irregular daily eating habits or poor sleep are connected to elevated risk for both obesity and IR. Further, circadian clocks disruption might also be an important factor to IR development via various factors including clock gene mutations, disturbed sleep cycles, shift work and jet lag. Moreover, epidemiologic studies of different institutions showed that individuals with regular exercise, healthy diet (including more soluble fiber, colorful fruit, vegetables, green tea, or less intake of added sugars, carbs, trans-fat), limiting alcohol intake, avoiding smoking cigarettes and reduced levels of stress, which indeed increase insulin sensitivity. Collectively, there are many relatively simple things we can do to naturally increase insulin sensitivity but ensure professional healthcare consultant first before adding medication regimen.

Different investigations suggest that vitamin D supplementation might reduce IR in some people due to increasing insulin receptor genes transcription and anti-inflammatory properties, while some researchers found that Vitamin D has no effect on IR. Thus, further studies should be performed to discover more about the mechanism and the effect of vitamin D on insulin resistance. Both experimental (animals) and clinical studies have shown that many hormones can induce IR including glucocorticoids (GCs), cortisol, growth hormone, and human placental lactogen, which may decrease the insulin-suppressive effects on glucose production and reduce the insulin-stimulated glucose uptake. Several other clinical medications including anti-adrenergic (such as salbutamol, salmeterol, and formotero), HIV protease inhibitors, atypical antipsychotics, and some exogenous insulin that may improve IR because of the disordered insulin signaling. All together, there may have synergistic effects of different risk factors on insulin resistance, scientific researchers should cooperate with medical experts to reduce the chances of becoming insulin resistant.

The interorgan metabolic crosstalk in IR As described above, insulin signaling calibrates glucose homeostasis by limiting hepatic glucose output via decreased gluconeogenesis and glycogenolysis activities. These processes consequently increase the glucose uptake rates in muscle and adipose tissues. In addition, insulin profoundly affects lipid metabolism by increasing lipid synthesis in liver and fat cells (Fig. 3), in addition to switching-off fatty acid release from triglycerides (TG) in fat and muscle tissues.

Despite stimulated glucose uptake, insulin rapidly reduces hepatic glucose output and hepatic glucose production (HGP) by activating glycogen synthesis, and suppressing glycogenolysis and gluconeogenesis in liver. Further, gluconeogenesis suppression by insulin is mediated by inhibition of FOXO1 transcription factors. For example, some mouse models of profound hepatic IR exhibit increased G6pc (glucose-6-phosphatase) expression suggesting increased FOXO1 activity. Moreover, correct hepatocellular insulin action also carries suppression of hepatic glycogenolysis and stimulation of glycogenesis. A remaining question is whether potential controlling factors including allosteric control of glycogen synthase (GS) and phosphorylases via glucose-6-phosphate (G6P), in addition to the insulin-independent transport of glucose across the hepatocellular plasma membrane by GLUT2 (as a glucose-sensitive protein in liver cells), can impact hepatic glycogen metabolism. Loss of GLUT2 leads to a typical combination of hepatic glycogen accumulation, glucose intolerance, and fasting hypoglycemia. In addition, liver insulin also effectively regulates lipid metabolism primarily by promoting cleavage and nuclear translocation of the sterol regulatory element binding protein 1c (SREBP-1c) that activates lipogenesis in hepatocytes. Insulin induces SREBP-1c maturation via a proteolytic mechanism started in the endoplasmic reticulum (ER), wherein hepatic IR is highly associated with hepatic steatosis. Over-expression of liver SREBP-1c has been described in several IR models of including IRS2 knockout, lipodystrophic and ob/ob mice. In addition, hepatic glucose lead to a deficiency in the transcription factor carbohydrate responsive element binding protein (CHREBP) resulting in reduced mRNA levels of glycolytic and lipogenic enzymes, as well as SREBP-1c levels. Accordingly, restoration of nuclear SREBP-1c expression in liver-specific Chrebp defective mice normalized expression of some lipogenic genes, while not affecting glycolytic genes expressing. In contrast, CHREBP overexpression alone failed to promote the expression of lipogenic genes in the livers of mice lacking active SREBPs. Together, these data demonstrate that SREBP-1c mediates the induction of insulin lipogenic genes, but that SREBP-1c and CHREBP are both necessary for harmonious induction of glycolytic and lipogenic genes.

The lipid metabolisms including increased de novo lipogenesis and attenuation of lipolysis in the adipose tissue largely coordinate with glucose homeostasis response to insulin stimulation. De novo lipogenesis regulation in adipose is similar to that in livers, wherein adipose-ChREBP is a major determinant of adipose tissue fatty acid production and systemic insulin sensitivity, that is induced by GLUT4-mediated glucose uptake, and genetically ablating CHREBP impairs insulin sensitivity in adipose tissue. In addition, lipogenic gene FASN and DGAT mRNA expression in adipose tissue have been shown to correlate strongly and positively with insulin sensitivity, which were may reduced by larger adipocytes in adipose tissue of obese individuals. The lipogenesis stimulation of insulin is also reduced in larger, more insulin-resistant cells. Insulin suppression of lipolysis includes the hydrolytic cleavage of triglycerides, resulting in the generation of fatty acids and glycerol. The best understood effectors for this process are PDE3B and ABHD15 that operate by the suppression of cAMP to attenuate pro-lipolytic PKA signaling toward adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and perilipin (PLIN). Phosphorylation and activation of PDE3B at Ser273 and Ser296 by AKT is a key event in antilipolysis after insulin stimulation. Further, inhibition of PDE3B inhibits insulin-induced glucose uptake and antilipolysis. Pde3b knockout mice exhibit impaired suppression of plasma NEFA levels and corresponding impairment in hepatic glucose production suppression during glucose tolerance tests. Further, mice homozygous for the Plin1 deletion exhibit high basal lipolysis and are unresponsive to adrenergic stimulation, confirming that PLIN is actively controls lipolysis. Taken together, all the evidence supports that white adipose tissue (WAT) lipolysis suppression of insulin also associated with hepatic gluconeogenesis, and the mechanisms of IR include complex mediators and metabolic networks.

Insulin stimulated protein synthesis is mediated by activation of the protein kinases Akt and mTOR (specifically mTORC1 and mTORC2) in numerous insulin-responsive cell types, such as hepatocytes, adipocytes, and myocytes. AKT also phosphorylates the TSC1-TSC2 complex to relieve its inhibition on the mTORC1. Inhibition of mTOR by rapamycin obviously impairs insulin-activated protein synthesis. Recent studies have
identified that Akt phosphorylates and inactivates the PRAS40 (proline-rich Akt/PKB substrate 40), which abates its binding inhibition of mTOR signaling and promotes protein synthesis. Amino acids metabolic substrates enhance insulin sensitivity and responsiveness of the protein synthesis system by increasing mTOR activity and inhibiting protein degradation in liver, muscle, and heart tissues. Skeletal muscle tissue is the largest protein/amino acid (AA) reservoir in the human body, and lower muscle protein synthesis (MPS) induces fed-state anabolic resistance,134 in addition to exercise training of the Akt/mTOR pathway. These processes, in turn, promote protein synthesis and antagonize protein degradation. PRAS40 and mTOR also exerts negative feedbacks on proximal insulin signaling, PRAS40 knockdown significantly decreases Akt phosphorylation, mTORC1 binds and inhibits INSR by inducing destabilization of IRS1.28 The signaling system of IR are multifactorial including different metabolic pathways, such as glucose, lipid, and protein, identifying new molecules will be crucial to unraveling more effective treatment of IR and associated metabolic diseases.

The contribution of metabolic mediators to IR

Adipokines dysregulation and IR. Adipose tissue can secrete various bioactive circulating mediators referred as ‘adipokines’, like adiponectin, leptin, chemerin, resistin, visfatin and vaspmin, in addition to cytokines and chemokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1β, and monocyte chemoattractant protein-1.136 Dysregulation of these adipokines has been implicated in the onset of obesity, IR, type 2 diabetes, cardiovascular disease, hypertension and metabolic syndromes.137

Adiponectin is the most abundant protein secreted by adipose tissue and exhibits potent anti-inflammatory properties.138 It has been closely associated with improved insulin sensitivity and metabolic health. Adiponectin activates the AMPK and PPAR-α signaling pathways through adiponectin receptor 1 (AdipoR1) and AdipoR2 respectively, leading to enhanced fatty acid oxidation and glucose uptake in muscle, along with suppressed gluconeogenesis in liver tissues. Moreover, targeted disruption of AdipoR1 results in halted adiponectin-induced AMPK activation, increased endogenous glucose production and increased IR. Similarly, AdipoR2 deletion results in decreased PPAR-α signaling pathway activity and IR. In addition, chemerin is a chemokine highly expressed in liver and white adipose tissue that regulates the expression of adipocyte genes involved in glucose and lipid homeostasis like IRS-1 tyrosine phosphorylation activity, GLUT4, fatty acid synthase and adiponectin.141,142 Adiponectin and adiponectin receptor 1 (AdipoR1) and AdipoR2 respectively, play crucial roles in insulin sensitivity and resistance.

Leptin is a cytokine encoded by ob gene and produced by the adipocytes.147 Leptin binds to the leptin receptor (LepRb) and activates JAK2/STAT3 pathway to decrease body weight and normalizes blood glucose concentration, meanwhile, JAK2 stimulates the phosphorylation of insulin receptor substrate (IRS1/2), then activates PI3K/Akt pathway and directly affect insulin action. Leptin limits insulin synthesis and secretion from pancreatic β-cells, resulting in increased insulin sensitivity, reduced hepatic glucose production and decreased glucagon levels. In turn, insulin also plays a role in leptin production stimulation and secretion in adipose tissues. Leptin-deficient mice (ob/ob) causes both obesity and diabetes due to hyperphagia and blunted metabolic rate, and treatment with exogenous leptin could prevent and reverse the obese phenotype. Moreover, the decreased permeability of the brain-blood barrier (BBB) to leptin and impaired leptin signal transduction in neurons will lead to leptin resistance in obesity. Specifically, high
serum leptin levels connected to IR likely promote the the release of pro-inflammatory compounds that include IL-6, TNF-α, and IL-12 by monocytes and macrophages. Together, leptin and insulin share pivotal roles in the regulating glucose metabolism, and additional studies are needed to understand the effects of leptin on glucose-insulin homeostasis. In summary, adipose tissue is a central node for distinct adipokines and bioactive mediators in IR pathophysiology. Consequently, identifying the effects of new adipokines will help in the development of new therapeutic strategies for obesity-induced diseases.

**Fatty acid/lipid metabolism in IR.** The specific insulin actions in adipose tissue include activation of glucose uptake and triglyceride synthesis, suppression of triglyceride hydrolysis and free fatty acids (FFA) and glycerol release into the blood circulation. Among these actions, an extremely important function of adipose tissue is via the switches that favor lipids storage in adipocytes over their release into circulation upon need. Once the adipose tissue expandability exceeded limit under overnutrition, excess lipids and toxic lipid metabolites (FFA, diacylglycerol, ceramide) accumulated in non-adipose tissues, thus leading to lipid-induced toxicity (lipotoxicity) and developed IR in liver and muscle. The early mechanism of lipid accumulation puch plasma fatty acid to induce the IR as detailed in glucose-fatty acid cycle proposed by Randle and colleagues. Their hypothesis suggested that available fatty acids promote fatty acid oxidation and cause the accumulation of mitochondrial acetyl coenzyme A (CoA) and NADH, with subsequent inactivation of pyruvate dehydrogenase. This process would in turn induce increased intracellular citrate levels, thereby inhibiting glucose-6-phosphate (G6P) accumulation. Increased G6P levels then result in decreased hexokinase activity, increased glucose accumulation, and reduced glucose uptake. Other studies have demonstrated the relevance of the glucose-fatty acid cycle to lipid-induced IR. For example, lipid infusions combined with heparin can be used to activate lipoprotein lipase, thereby increasing plasma concentrations of fatty acids. Further, these infusions promote muscle lipid accumulation and effectively induce IR. In addition, contrary to predicted increases based on the Randle hypothesis, elevated free fatty acid levels were associated with reduced intracellular G6P levels in acute lipid-induced IR and type 2 diabetes. In parallel, lipid-induced IR in skeletal muscle leads to deficient insulin signaling and decreased insulin-stimulated glucose transport mediated by GLUT4 translocation, and not by glycolysis inhibition as Randle hypothesized. Together, these researchs suggest that lipid ectopic accumulation is directly correlated with IR.

**Diacylglycerol and ceramide accumulation.** Consistent with the above studies, elevated plasma fatty acid concentrations can result in increased intracellular diacylglycerol (DAG) levels, leading to the activation of protein kinase C isofrom (PKCθ) and PKCe isoforms in skeletal muscles and liver respectively. These processes, in turn, decrease insulin-stimulated IRS-1/IRS-2 tyrosine phosphorylation, PI3K activation and downstream insulin signaling that then induces IR in muscles and livers. Deletion of PKCθ in mice inhibits muscle IR is induced by lipid infusion. Moreover, knockdown of PKCe in rats leads to protection from fat-induced hepatic IR. These results confirm the distinct roles of PKCθ and PKCe in fat-induced IR in skeletal muscles and livers, respectively. Since diacylglycerol acyltransferase 1 (DGAT1) can increase the conversion of DAG into triacylglycerol (TAG), DGAT1 overexpression could decrease DAG levels and improve insulin sensitivity partially attenuating the fat-induced activation of DAG-responsive PKCs. Conversely, DGAT1 ablation may result in elevated DAG levels and lipid-induced IR. Taken together, these studies strongly support that DAG as a key intermediate of TAG synthesis from fatty acids has central modulation and potential therapeudic values in IR.

Ceramide is another specific lipid metabolite that increases in concentration, along with DAG, in association with IR in obese mice. Accumulated ceramide mediates the activation of protein phosphatase 2A (PP2A) and impairs insulin-dependent activation, in addition to signaling of PI3K/Akt by PKCζ thereby also disrupting lipid metabolism by inhibiting oxidation and stimulating fatty acid uptake. In particular, C18- and C16-long-chain ceramides that are produced by ceramide synthase isoforms (CerS1, CerS5, and CerS6) have higher concentrations in insulin-resistant tissues. Consistently, C18-derived ceramides play an important role in fat-induced skeletal muscle IR. Likewise, C16-ceramides exist in higher concentrations in obese adipose tissue and are associated with hepatic IR. Several lines of evidence suggest that circulating adiponectin is closely related to ceramide concentrations, wherein adiponectin increases ceramide activity associated with its two receptors Adipor1/Adipor2, while lower concentrations of circulating adiponectin increases ceramide concentrations in different tissues. Furthermore, inhibited ceramide synthesis or stimulation of ceramide degradation can prevent the effects of ceramide on Akt/PKB activation and improve insulin signaling. Thus, ectopic lipid metabolite concentrations (e.g., diacylglycerols and ceramides) may be mechanistic factors underlying liver and muscle IR. Consequently, concerted efforts to decrease lipid components in these organs are the most efficacious therapeutic targets for treating IR and metabolic diseases.

**Genetic mutations in IR**

Some human genetic studies indicated that different genomic loci were associated with fasting insulin levels, higher triglyceride and lower HDL cholesterol levels, which are different hallmarks of IR. Epidemiological and family genetic studies have provided considerable evidence for the genetic basis of both IR and the individual components of the metabolic syndromes. Since 2007, genome-wide association studies (GWAS) and next-generation sequencing (NGS) have identified different genetic variants associated with IR, including PPARG, IRS1, IGF1, ATF2, KL1F4, GCKR, FTO, TCF7L2, TMEM163, MC4R, SC4MOL, TCERG1L, and ARLO which by influencing insulin action via different regulatory mechanisms.

The peroxisome proliferator-activated receptor gamma (PPARγ) variant Pro12Ala was one of the first genetic variants identified that is involved in fatty acid and energy metabolism and that is associated with a low risk of developing T2DM. Variants (A allele at G allele) within IGF-1 insulin-like growth factor 1 contribute to its low plasma levels, and cause a reduction in insulin sensitivity. A variant in N-acetyltransferase 2 (NAT2) was recently identified as an insulin sensitivity gene. Adiponectin is an adipokine involved in improving insulin sensitivity, variants within ADP ribosylation factor like GTPase 15 are associated with decreased adiponectin levels and nominally associated with IR. Despite these potential genetic correlates, variants account for only 25% to 44% of the heritability of IR. Consequently, the contributions of low-frequency and rare genetic variants towards the heritability of IR have also been explored through a combination of both genome and exosome sequencing. Such studies have identified a low-frequency variant of CD300LG that is associated with fasting high-density lipoprotein cholesterol (HDL-C) and a TBC1D4 variant that together are connected to higher fasting glucose levels and reduced insulin sensitivity. The rapid development of genomics methods has enabled considerable progress towards the identification of genetic loci associated with IR by direct or indirect effects. Nevertheless, additional studies are needed to assess the functional relationships between the genetic variants and IR, that are also influenced by various lifestyle and environmental factors.
Epigenetic dysregulation in IR

Recent studies have suggested that epigenetic modifications such as DNA methylation (DNAm) and histone post-translational modifications (PTM) are implicated in the development of systemic IR.\(^{200,201}\)

DNA methylation. Global and site-specific DNA methylation is generally mediated by DNA methyltransferases (DNMTs). These processes mainly occur in the context of CpG dinucleotides (CpGs) and promoter region, while also involving covalent addition or removal of methyl groups as a means to repress or stimulate transcription, respectively.\(^{202}\)

Firstly, DNA methylation regulates different insulin signaling genes, such as insulin (INS), insulin receptor substrate 1 (IRS1), Insulin-like growth factor-1 (IGF-1), Insulin-like growth factor-binding protein 1/2 (IGFBP-1/2), phosphatidylinositol 3-kinase regulatory subunit PIK3R1, and Glucagon-like peptide-1 receptor (GLP-1).\(^{203-206}\) The methylation status of these genes was found to be altered in obesity and IR. For example, increased INS promoter methylation levels and INS mRNA suppression were observed under over-nutrition conditions and obese T2DM patients.\(^{207}\)

Similarly, a research with blood samples of T2DM found that increased IGFBP1 DNA methylation were associated with reduced IGF-I serum levels in T2DM patients.\(^{208}\) Insulin-like growth factor binding proteins 1 and 2 (IGFBP1 and IGFBP2, respectively) are the most abundant circulating IGFBPs and have lower concentrations in adipose tissue in obese patients, in addition to being negatively associated with hyperinsulinemia and IR.\(^{209}\)

Several studies have indicated that increased IGFBP-1 DNA methylation levels and decreased IGFBP-1 serum levels are associated with newly diagnosed T2DM. Another study demonstrated\(^{210}\) that increased IGFBP2 DNA methylation levels were associated with lower mRNA expression levels in Visceral Adipose tissue (VAT) of abdominal obesity. Moreover, the first global genome-wide epigenetic analysis in VAT\(^{211}\) from IR and insulin-sensitive (IS) morbidly obese patients identified a novel IR-related gene, the zinc finger protein 714 (ZNF714) exhibited the highest DNA methylation difference, and its methylation levels is lower in IR patient than in IS patient, consistent with increased transcription levels, such studies provide potential epigenetic biomarkers related to IR in addition to novel treatment targets for the prevention and treatment of metabolic disorders.

Some DNA methylation in the promoter regions of specific genes related to lipid metabolism (PPARG, PPARα,\(^{212}\) low-density lipoprotein receptor-related protein 1 (LRP1),\(^{213}\) lipoprotein lipase (LPL),\(^{214}\) SREBF1/2,\(^{215}\) and inflammation (stearyl-CoA desaturase 1 (SCD1), chemokine C-C motif chemokine ligand 2 (CCL2), TNF-α, and TGF-β)\(^{216,217}\) are associated with adipose tissue dysfunction and could lead to metabolic disorders. For example, peroxisome proliferator-activated receptor-α and γ (PPAR-α and PPAR-γ, respectively) are encoded by PPARA and PPARγ, respectively, and they are the two primary nuclear peroxisome proliferator-activated receptors involved in lipid metabolism. Higher PPARα and PPARγ methylation levels were observed in association with obesity, consistent with decreased PPAR-α and PPAR-γ protein expression levels,\(^{218,219}\) that lead to dyslipidemia and IR. SLC19A1, a gene encoding a membrane folate carrier, was reduced in obese WAT and induced global DNA hypermethylation of chemokine C-C motif chemokine ligand 2 (CCL2) that is a key factor in WAT inflammation,\(^{220}\) resulting in increased CCL2 protein secretion and the development of IR in obese.

In addition, several genes methylation involved in hypoxia stress and endoplasmic reticulum stress were regulated in obesity related metabolic diseases.\(^{220}\) Hypoxia-inducible factor-3α (HIF3A) belongs to the hypoxia-inducible factors family (HIFs) that play important roles in the pathogenesis of obesity-induced IR, adipose tissue-inflammation and the etiology of obesity related disease. Recent epigenetic genome-wide analysis identified low HIF3A methylation levels upregulates HIF3A expression in adipose tissue, thereby leading to adipose tissue dysfunction and adiposity.\(^{221}\) Further, reduced HIF3A methylation and increased HIF3A levels in blood are associated with IR and higher body mass index (BMI) values in T2DM patients.\(^{222}\) The major function of the endoplasmic reticulum (ER) is the synthesis and folding of secreted and transmembrane proteins, increasing evidence suggests that persistent ER stress is associated with the onset and progress of chronic metabolic disorders like obesity and IR. Ramos-Lopez et al.\(^{223}\) found that the methylation levels of four ER genes including ERO1LB, NFE2L2, MBTPS1 and Eif2ak4 which encoded ER oxidoreductin-1β (ERO1β), nuclear factor-erythroid 2-related factor (Nrf2), site-1 protease (S1P) and eif-2-alpha kinase (Gcn2) respectively, were strongly correlated with total body fat levels. Specifically, increased insulin concentrations and HOMA-IR index were accompanied by lower ERO1LB and NFE2L2 methylation levels.\(^{223}\) Hence, related to hypoxia and ER stress genes could be considered as precise therapeutics to control the IR.

Histone modifications. The histone modification effect on gene expression mainly includes histones methylation and acetylation. Histone methylation could either activate gene transcription (H3K4, H3K36, and H3K79) or silence gene expression (H3K9 and H3K27), which depends on the modification site.\(^{224}\) Several studies have reported various histone epigenetic modifications of metabolic and mitogenic cascade-related genes of insulin signaling during IR.\(^{225}\) PPARG is a key transcription factors that regulates insulin sensitivity, lower histone H3 acetylation and methylation of the PPARG gene are associated with reduced PPARG expression that is associated with IR.\(^{226}\) Further, increased expression and low methylation of CDKN1A and PDE7B genes in T2DM can lead to impaired insulin release that is stimulated by glucose in T2DM patients.\(^{227}\) The high level of H3K4 trimethyl (H3K4me3) of Fxyd3 gene negatively regulates the glucose capacity of insulin-secreting cells in mice.\(^{228}\)

Histone acetylation increases the accessibility and gene expression of various transcription factors by reducing the positive charge and histone affinity for DNA.\(^{229}\) Histone deacetylation is considered to be the inhibition of DNA assembly by chromatin condensation and transcription factors, resulting in transcriptional inhibition. Increasing evidence indicates\(^{229,230}\) that IGFR, InsR, IRS1, Akt, GLUT4, and PPAR are more deacetylated in association with IR than in normal physiological conditions. In contrast, IRS2, FoxO, JNK, and IRMPK are usually acetylated in association with IR. Castellano-Castillo, D. et al. utilized a chromatin immunoprecipitation (ChIP) assay to determine that the human adipose tissue H3K4me3 histone mark site in adipogenic, lipid metabolism, and inflammatory genes (such as LEP, LPL, SREBF2, SCD1, PPARγ, IL6, TNF, and E2F1) is positively associated with BMI and HOMA-IR. Further, global proteomic analyses have revealed 15 histone modifications that are differentially abundant in hepatic IR.\(^{232}\) These observations provide evidence for diabetes-related histone modification and related impaired insulin release.

non-coding RNA regulation in IR

Non-coding RNAs (ncRNAs) comprise approximately 98% of human genome transcripts and are generally not translated into proteins.\(^{233}\) The rising studies\(^{234-235}\) have shown that ncRNAs include microRNAs (miRNAs), long non-coding RNAs (IncRNAs) and circular RNAs (circRNAs) are key mediators in the pathogenesis and progression of metabolic homeostasis.\(^{236}\) MicroRNAs (miRNAs) are small ncRNAs (18-22 nucleotides) incorporated into Argonaute (Ago) protein to form miRISCs, which can inhibit the expression of partially or completely complementary target mRNAs.\(^{236}\) Dysregulation of various miRNAs within different fluids (e.g., blood, saliva, and urine) is associated with obesity and IR development, including
β-cell dysfunction, glucose and lipid homeostasis, and chronic inflammation.237

Firstly, pancreatic β cell mass due to dysfunction and/or death are the major cause of insufficient insulin secretion, and the main common mechanisms of T1DM and T2DM. Several miRNAs are involved in β cell differentiation and mature β cell functioning. For example, islet-specific miR-375 overexpression represses glucose-stimulated insulin secretion (GSIS) and insulin gene transcription, that is then reversed upon miR-375 inhibition.238 Further, deregulated plasma levels of miR-375 together with miR-150, miR-30a-5p, and miR-15a are observed before T2DM and pre-diabetes onset. Thus, these markers may improve disease prediction and prevention in individuals at high risk for T2DM.239

Other miRNAs have been implicated in β-cell proliferation and insulin secretion regulation during IR including miR-124a2, miR-204, miR-184 and miR-24. Further, miR-124a2 targets the genes encoding cAMP-response-element binding protein (creb-1) and forkhead/winged helix transcription factor boxa2 (foxA2) mRNA.240

FoxA2 is an upstream regulator of pancreatic duodenal homeobox 1 (pdx1) that is essential for pancreatic development and glucose homeostasis. Furthermore, pdx1, neurogenin-3 (ngn3), and a transcriptional factor essential for insulin transcription (Mafa) are essential transcription factors for β-cell differentiation. Thus, miR-124a2 can directly modulate insulin expression through foxA2 and then pdx1, miR-204 expression is induced by the cellular redox regulator thioredoxin-interacting protein (TXNIP) that then represses Mafa, thereby inhibiting insulin production.241

In addition, miR-185-5p overexpression enhances insulin secretion and promotes pancreatic β-cell proliferation by targeting SOCS3 and regulating the Stat3 pathway.242

Numerous studies suggest that miRNAs have pivotal roles in glucose and lipid metabolism.243,244 As we mentioned above, glucose metabolism contains different processes including glucose transport, glucose uptake, gluconeogenesis and glycogenolysis. miR-93 was first reported to directly regulate GLUT4 expression in adipocytes.245 Further, miR-29 and miR-31 regulate GLUT4 expression in skeletal muscle and adipose tissues of T2DM patients, respectively. In addition, miR-27a/b levels are higher in the sera of patients with type 2 diabetes, while miR-27a/b overexpression suppresses hepatic glucose output and alleviates hyperglycemia by targeting FOXO1.246 Moreover, elevated miR-338-3p levels are responsible for decreased glycogenolysis and subsequent glucose accumulation by directly targeting the glycogen phosphor-

lyase brain form (PYGB).247 miR-185-5p overexpression in diabetic mice that represent genetic diabetes models leads to alleviated blood hyperglycemia and decreased gluconeogenesis by directly targeting glucose-6-phosphatase (G6Pase). In addition, the anti-diabetic drug metformin can up-regulate miR-185-5p expression to suppress G6Pase and inhibit hepatic gluconeogenesis.248

The balance of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) molecules that are synthesized in hepatocytes is critical for lipid homeostasis. Many miRNAs have been identified as critical regulators of HDL and LDL biogenesis. For example, miR-33, miR-128-1, miR-144, and miR-148a repress expression of the ATP-binding cassette transporter ABCA1 that mediates hepatic HDL generation.250,251 Thus, inhibition of these miRNAs increases circulating HDL levels. In addition, miR-30c targets the gene encoding microsomal triglyceride transfer protein (MTP) that is required for the lipidation of newly synthesized APOB in the liver for LD lipoprotein production. miR-30c overexpression reduces the assembly and secretion of these APOB-containing lipoproteins, resulting in decreased plasma LDL levels.252 The LDL receptor (LDLR) of hepatocytes is highly expressed and binds LDLs, clearing them from circulation. miR-148a and miR-128-1 repress LDLR expression and inhibition of these miRNAs results in enhanced LDLR expression and clearance of circulating LDL. Further, miR-224 and miR-520d target the LDLR chaperonin PCSK9 and IDOL in addition to the rate-limiting enzyme in cholesterol biosynthesis, HMGCR.254 In addition, inhibition of PCSK9, IDOL, and HMGCR by miR-224 and miR-520d was associated with increased LDLR protein levels and increased LDL binding, resulting in decreased plasma LDL cholesterol levels.

Chronic inflammation in insulin-reactive tissues is one of the most important causes of IR and increasing evidence suggests that miRNAs has a pivotal role in the inflammatory process. Obesity inhibited miR-30 expression in adipose tissue macrophages (ATMs), and miR-30 was shown to target Delta-like-4 (DLL4), a Notch1 ligand is associated with ATM inflammation.255 miR-30 inhibition triggers Notch1 signaling, pro-inflammatory cytokine (TNFα and CCL2) production, and M1 macrophage polarization, indicating that miR-30 manipulation could be a therapeutic approach for reducing obesity-induced inflammation. Conversely, Wang et al. discovered that miR-1249-3p is significantly upregulated in Natural killer (NK) cells-derived exosomes from lean mice, which directly targets SKI family transcriptional corepressor 1 (SKOR1), subsequently downregulated the expression levels of pro-inflammatory cytokine factors (including IL-1β, IL-6, and TNF-α) levels and attenuated IR. Therefore, it might be that metabolism-regulating miRNAs play a vital role in the dynamics of metabolic homeostasis.256

**LncRNAs and IR.** Long non-coding RNAs (lncRNAs) are non-coding transcripts more than 200 nucleotides, and the subcellular localization of lncRNAs determines their function. LncRNAs located in the nucleus could affect chromosomal biology or interact with transcription factors to regulate gene transcription; lncRNAs located in cytosol could modulate mRNA stability and translational efficiency by acting as sponges for miRNAs or direct pairing with mRNA. Recent advances have shown that lncRNAs play crucial roles in the pathologies of IR and diabetes.213,238,259

Glucose and lipid metabolism disorders are the primary causes for the pathophysiological development of IR. The IncRNA SRA promotes insulin-stimulated glucose uptake by co-activating PPARY, leading to increased phosphorylation of the downstream targets Akt and FOXO1 in adipocytes.260 Furthermore, glucagon-stimulated upregulation of H19 via the AMP/PKA pathway induces nuclear translocation of HNF4A and activates the transcription of G6PC and PCK that are involved in gluconeogenesis, resulting in hepatic glucose production.261 In addition, the H19 sponge cell miR-130a induces PPARY nuclear translocation, thereby activating the transcription of adenopigenic genes like those encoding acetyl coenzyme a carboxylase 1 (ACC1), fatty acid synthase (FAS), and cytoskeleton-related genes (SCD1), thereby promoting intracellular lipid accumulation.262 H19 is downregulated in skeletal muscles of db/db mice and interacts with heterogeneous nuclear ribonucleo-

protein (hnRNPA1) that then increases fatty acid oxidation (FFA) protein translation. These processes are closely related to the genes PGC1α and CPT1b that reverse FFA-induced lipid accumulation and improve IR.263 This suggests the complex effect of lncRNAs on the IR progression.

In addition the insulin target tissues,264 transcriptome profiling and different studies have identified several β-cell specific IncRNAs that contribute to obesity-mediated β-cell dysfunction and apoptosis. LncRNA MALAT1 downregulation may lead to pancreatic β-cell dysfunction and T2DM development by direct interaction and regulation of polyomipridine bundle binding protein 1 (PTBP1). The IncRNA-p3134 positively regulates GSIS by promoting P13K/Akt/mTOR signaling and the key regulators (Pdx-1, Mafa, GLUT2, and Tcf7l2) in pancreatic β cells. Further, IncRNA-p3134 overexpression can decrease the β cell apoptosis ratio and partially reverse the glucotoxicity effects on GSIS function.265,266 Similarly, the newly identified IncRNA β-cell function and apoptosis regulator (βFaa) ameliorates obesity-associated β-cell dysfunction and apoptosis by upregulating the islet-specific genes (Ins2, NeuroD1, and Creb1) by sponging miR-138-5p.267 In addition, a novel micropeptide TUNAR encoded by IncRNA transcripts play a critical role in pancreatic β cell functions and insulin
Collectively, these studies provide new insights into the use of IncRNAs as possible biomarkers or therapeutic targets for obesity-associated IR and metabolic diseases.

**Circular RNAs (circRNAs) and IR.** Contrary to conventional linear RNA, circRNAs are noncoding RNAs that generated from precursor mRNAs by back-splicing circularization, which is derived from exonic circRNAs, intronic circRNAs, exonic-intronic circRNAs and ntergenic circRNAs. CircRNAs can affect gene transcription, splicing and translation by acting as a miRNA sponges, binding to RNA binding proteins or transcription factors (TFs). Recent studies have suggested that newly identified circRNAs are novel factors in the initiation and development of IR. For example, ci-ins2 is a conserved intronic circRNA derived from insulin pre-mRNA that exhibits lower levels in the islets of rodents and humans with type 2 diabetes. ci-ins2 silencing in pancreatic islets leads to decreased expression of several genes important for insulin secretion (Rapgfe4, Pld1, Pclo, and Cacna1c) by interacting with the TAR DNA-binding protein 43 (TPD43), thereby contributing to β-cell dysfunction during diabetes. CircHIK3 is one of the most abundant circRNAs in β-cells and regulates hyperglycemia and IR by sequestering miR-124-3p and increasing mRNA expression of key genes (e.g., Sla2a2, Akt1, and Mtprn), insulin secretion, and β-cell proliferation. A similar effect of circHIK3 on hyperglycemia and IR has been observed by sponging miR-192-5p and increasing FOXO1 expression. In addition, Hsa_circ_0054633 suppression promotes β-cell proliferation and facilitates insulin secretion through inhibiting caspase-8 expression by sponging miR-409-3p. These recent results point to circRNAs as novel regulators of β-cell dysfunction under diabetic conditions.

Similar to the miRNAs and IncRNAs, several circRNAs also contribute to the regulation of glucose and lipid homeostasis. Li et al. first demonstrated that circRNA-1897 is highly down-regulated in the subcutaneous tissues of two pig breeds, and that it directly targets miR-124-3p and miR-338-3p, thereby increasing miRNA expression of key β-cell genes (e.g., Sla2a2, Akt1, and Mtprn), insulin secretion, and β-cell proliferation. A similar effect of circHIK3 on hyperglycemia and IR has been observed by sponging miR-192-5p and increasing FOXO1 expression. In addition, Hsa_circ_0054633 suppression promotes β-cell proliferation and facilitates insulin secretion through inhibiting caspase-8 expression by sponging miR-409-3p. These recent results point to circRNAs as novel regulators of β-cell dysfunction under diabetic conditions.

**AMPK is a critical factor in energy homeostasis including glycolysis, lipolysis, and fatty acid oxidation (FAO). CircACC1 is a circRNA derived from the human acetyl-CoA carboxylase 1 (ACC1) gene and directly binds to the β and γ subunits of AMPK, facilitating its activity and promoting glycolysis and fatty acid β-oxidation during metabolic stress. CircMAPK3K4 is another potentially important circRNA involved in glucose metabolism that is highly expressed in the placenta of patients with gestational diabetes mellitus (GDM) and the IR model. circMAPK3K4 can suppress the insulin-Pi3K/Akt signaling pathway via the miR-6795-5p/PPTP1 axis, thereby contributing to GDM-associated IR. Nevertheless, the exact roles and regulatory mechanisms of circRNAs in IR require additional clarity.

**Involvement of the gut microbiota in IR**

**Influencing factors of Gut microbiome composition.** The microbes living in the human gut are key contributors to host metabolism and immune function through mediating the interaction between the host and environment, or releasing metabolites and cytokines. In 2012, the Human Microbiome Project Consortium began to show that the gut microbial phyla in humans mainly consist of the gram-positive Firmicutes, gram-negative Bacteroidetes and Proteobacteria. Although the composition of human gut microbiota remains relatively stable from around age 3, gut microbiota undergoes the increase in diversity and altered proportions of composition.

Different factors influencing these alterations of gut microbiome composition have been explored including diet, exercise, circadian disruption, antibiotics treatments, and genetics. (1) Regarding diet: David et al. conducted a study of human wherein volunteers were placed on either a plant-based diet (i.e., with grains, legumes, fruits, and vegetables) or an animal product-based diet (i.e., with meats, eggs, and cheeses) for five consecutive days. The gut microbial communities of the groups significantly diverged over time, with participants on animal diets experiencing proliferation of bile-tolerant microorganisms (e.g., Alistipes, Bilophila, and Bacteroides) and decreased abundances of fiber-fermenting bacteria. Furthermore, differences in gut microbiota exists between humans with western diets rich in lipids and animal proteins in comparison to African diets rich in millet/sorghum and local vegetables, with little contribution of lipids and animal proteins to diets. (2) With regards to exercise, recent studies have highlighted the capacity of exercise to increase the abundances of beneficial gut microbial species, increasing gut microflora diversity, improving the proliferation of commensal bacteria, and reducing inflammation in addition to intestinal permeability. (3) Circadian disruption: both human and non-human models examination indicate that insufficient sleep (less than 7 h sleep per night) and circadian misalignment (such as workforce with shift workers or social jetlag) may lead to modifications in gut microbiota compositions, structure, and function. (4) Antibiotics: In deed, short-time antibiotic exposures can directly perturb the gut microbiota, reduce bacterial diversity and metabolic activity, disrupt intestinal integrity, which is a major cause for concern in human health. (5) Host genetics also shape the composition of the gut microbiome. For example, microbiome genome-wide association studies (mGWAS) have identified that variants of different genes (for example, VDR, LCT, NOD2, FUT2, and APOA2) that are associated with distinct gut microbiome compositions. Furthermore, 16S ribosomal RNA (16S rRNA) sequencing with microbiome analysis revealed that some species (especially from the phyla Firmicutes and Verrucomicrobia) in the gut microbiota are heritable. Thus, how to modulate the gut microbiota based on internal and external factors is important to maintain the public health.

**Gut microbiome dysbiosis involved in IR.** Growing evidence in the last two decades has suggested that gut microbial dysbiosis contributes to increased risks of metabolic defects like obesity, IR, and diabetes. For example, several studies have shown that obese adults harbor reduced gut microbial diversity and altered microbiota compositions compared with adults exhibiting normal weight. Another study of sixty-eight obese young patients revealed reduced fecal bacterial richness in patients with IR and high diastolic blood pressure (BP). Moreover, distinct microbial population markers were associated with impaired glucose tolerance, high BP, and low high-density lipoprotein cholesterol. A whole-genome sequencing investigation of the intestinal microbiota from 49 obese adults revealed that low bacterial gene counts were associated with unhealthy phenotypes like higher IR, dyslipidemia, and inflammation compared to adults with higher bacterial gene counts. While the exact roles of gut microbiomes in IR remain incompletely understood, many studies have nevertheless begun to elucidate the mechanisms by which gut microbiome dysbiosis produces different signaling activation. For example, gut microbiota can influence host glucose metabolism and hormone production via the production of several metabolites like short-chain fatty acids (SCFAs, mainly including acetate, propionate, and butyrate) and bile acids. Hyperglycemia then increases gut permeability and subsequent translocation of bacterial lipopolysaccharide (LPS) into systemic circulation. LPS circulation then contributes to the chronic
inflammation of liver and adipose tissue that is associated with the development of IR, in addition to other conditions associated with metabolic syndromes.301 The potential mechanisms related to gut microbiome activities and IR are very complex, and numerous studies with contradictory results render it difficult to identify clear mechanistic pathways. Nevertheless, some strategies have been developed to modulate microbiota, such as fecal microbiota transplants, probiotics or prebiotics supplementation, in combination with medications and/or healthy lifestyle, in hope to ameliorate microbiota composition and IR.302,303

IR RELATED DISEASES IN HUMAN

As we all know, IR is a state in which higher than normal concentrations of insulin are needed for a normal response, leading directly to hyperinsulinaemia and impaired glucose tolerance.304 As mentioned above, the primary characteristics of IR are inhibited lipolysis in adipose tissue, impaired glucose uptake by muscle and inhibited gluconeogenesis in liver.305 Nevertheless, IR can be linked to a cluster of abnormal syndrome (Fig. 4), which include obesity, diabetes, Nonalcoholic fatty liver disease, cardiovascular disease, polycystic ovary syndrome, and other abnormalities.306–308 Since obesity and diabetes have been discussed in the previous content, this part we mainly summarize other related metabolic syndrome in human.

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) and IR Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide.309 It includes a series of diseases, such as simple fatty liver (hepatic steatosis), non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma.310 Recently, a consensus of international experts proposed that the disease acronym have to be changed from NAFLD to metabolic (dysfunction) associated fatty liver disease (MAFLD). Adipose tissue is a physiologic reservoir of fatty acids,311 when the storage capacity is exceeded, the associated fatty liver disease (MAFLD). Adipose tissue is a physiologic DAG content and PKC fatty acid synthesis and hepatic SREBP-1c overexpression increases tyrosine kinase activity, thereby inducing hepatic IR.326,327 While ChREBP deficiency improves IR and hepatic steatosis by inhibiting the entire lipogenic and esterification process.328,329 Thus, inhibition of DNL and related pathway may effectively alleviate MAFLD and IR.

Polycystic ovary syndrome (PCOS) and IR Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disorder characterized by imbalances of multiple hormones that reflect the clinical manifestations of hyperandrogenism and affects 5%–10% of women of childbearing age.330,331 It is believed that IR and obesity play prevalent roles in causing PCOS, and PCOS women show an increased comorbidities of IR, including obesity, dyslipidemia, hypertension, and T2DM than healthy women.332–334 Specifically, IR leads to compensatory hyperinsulinemia, which stimulates Ghrn gene transcription through MAPK pathway in PCOS and increases LH pulse secretion, thereby significantly increasing ovarian androgen synthesis.12,332 In addition to directly interfering with insulin signaling, androgens may also trigger lipolysis and increase circulating FFA, thereby leading to IR.335 Moreover, androgens decrease the type I muscle fibers (TIMF) with highly oxidative and insulin-sensitive properties, while increase type II muscle fibers (TIMF) that are glycolytic and less insulin-sensitive, further decreasing glycogen synthase expression and favoring the development of IR in PCOS.336–338 This evidence supports that IR and hyperandrogenemia continuously stimulates each other in a vicious cycle under the condition of PCOS. At present, the molecular mechanism of insulin in PCOS has been well described. First of all, the defects downstream of insulin receptor phosphorylation, such as activation of phosphorylated IRS-1 through PKC or GLUT-4 translocation through PI3K/Akt signaling pathway, are the causes of IR in some PCOS women.339,340 Second, certain proinflammatory mediators including TNF, C-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1) and IL-18 levels are elevated in PCOS women independently of obesity.340–342 Furthermore, hyperglycemia may contribute to inflammation in PCOS, possibly by inducing oxidative stress via increased ROS production. Such modifications then activate NF-xB that is involved in the expression of proinflammatory mediators such as TNF and IL-6,343,344 and that induces key steroidogenic molecules, like CYP11A1, CYP17A1 and STAR, leading to further aggravation of hyperandrogenemia.345–347 Altogether, obesity and IR play pivotal role in women with PCOS and subsequent metabolic complications, and targeting these areas may become an important therapeutic approach for effectively reducing incidence of this pathology.

Cardiovascular disease and IR Cardiovascular diseases (CVDs) are the leading causes of death globally. The World Health Organization estimates that 17.9 million people live with CVDs each year, and CVD-related deaths accounted for 32% of all global deaths in 2019. Moreover, over 23 million people are estimated to die from CVDs each year by 2030.348–350 CVDs represent a general compromising abnormal conditions including any disorders of heart and blood vessels. However, the most common types of CVDs include high blood pressure, coronary artery disease (CAD), stroke, cerebrovascular disease and rheumatic heart disease (RHD).351,352 Currently, the mechanisms of IR contribute to cardiovascular diseases mainly include chronic hyperglycemia, dyslipidemia, endothelial dysfunction and inflammation.353,354 Specifically, the increased glucose-neogenesis and decreased glycogen synthesis in hepatic IR results in fasting hyperglycemia that increases total TG levels and blood pressure (BP), reduces HDL-C levels, and increases the risk of thrombosis formation.343,356 Moreover, long-term follow up data from patients with type 1 and type 2 diabetes have confirmed that hyperglycemia is a risk factor for CVD.357 IR in adipose tissue leads to high FFAs levels358 visceral fat accumulation that is associated with elevated levels of plasminogen activator inhibitor 1 (PAI-1) and BP,359 and ectopic lipid and toxic lipid metabolite accumulation (lipotoxicity) in blood vessels that alters cellular signaling and cardiac structure, thereby contributing to the increased
prevalence of cardiovascular diseases. Furthermore, IR induces dyslipidemia characterized by elevated serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or triglycerides (TG) along with reduced HDL-C concentrations, together which enhance the incidence of CVD by 32% in men and 76% in women. IR contributes to endothelial dysfunction by decreasing nitric oxide (NO) production via PI3K/Akt pathway from endothelial cells, and increasing reactive oxygen species (ROS) production, prothrombotic factors and proinflammatory markers mediated by MAPK/ERK activity, that both increases the cardiovascular risk, increased ROS levels in turn leads to the inhibition of insulin-PI3K signaling pathway through IRS-1 phosphorylation, which may aggravate IR. Overall, IR is a complex syndrome, which can significantly increase the risk of cardiovascular diseases. Identifying new therapies to reduce IR may contribute to the reduced prevalence of CVDs.

Alzheimer's disease and IR
Alzheimer's disease (AD) is a progressive neurodegenerative disease and is considered the sixth leading cause of death in the United States, with most patients aged 65 or older. Recent epidemiological studies have suggested that IR increases the risk for AD and related dementias. AD is actually a brain-specific form of diabetes that exhibit increased Aβ accumulation, tau hyperphosphorylation and impaired glucose transportation, energy metabolism, hippocampus and inflammatory pathways. Additional research has identified that insulin receptor is expressed on almost all cell types in the brain, with expression highest in the olfactory bulb, followed by the cerebral cortex, hippocampus, hypothalamus, and cerebellum. Thus, insulin signaling likely also carries important and diverse roles in brain functioning and AD pathogenesis. Insulin primarily enters the brain via selective, saturable transport across the blood-brain barrier (BBB). Peripherally produced insulin can also be actively transported into the brain via an endocytic-exocytic mechanism. Similar to systemic IR, brain IR can be defined as failed response to insulin by brain cells primarily due to downregulated insulin receptors, an inability of insulin receptors to bind insulin, or dysfunction of the insulin signaling cascade.

Current researches have demonstrated that the mechanisms of systemic IR and brain-specific IR have close links with AD pathogenesis. For example, major abnormalities in AD brains include decreased mRNA and protein expression levels of insulin, insulin receptors, insulin receptor substrate 1 (IRS1) and IGF1/2, in addition to reduced protein indicators of downstream insulin signaling activity (including phosphorylated AKT (pAKT) and phosphorylated GSK3β), tau mRNA, and increased amyloid precursor protein levels. Furthermore, recent evidence indicated that inflammation and lipid metabolism might contribute to the development of AD. Potential targets include PPARγ, Apolipoprotein E (ApoE), Apolipoprotein E receptor (LRP1), and leptin. Chronic inflammation exacerbates IR signaling that contributes to AD by provoking proinflammatory mediators including TNF-α, IL-6, and IL-1β. Among these mediators, IL-6 can stimulate amyloid precursor protein (APP) formation, and is often co-localized with Aβ plaques in AD patients. Thus, rosiglitazone has anti-inflammatory effect by decreasing levels of NFkB and inhibiting the Aβ42 production in mice, is considering as therapeutic agent for AD. Pioglitazone acts similarly as Rosiglitazone by reducing tau and Aβ deposits in the hippocampus, and improving neuronal plasticity and learning in AD. These
studies collectively suggest that IR contributes to AD pathogenesis through multiple pathways. Moreover, overlapping pathological features exist for diabetes, IR, and AD. Thus, the development of additional therapeutic drugs including anti-diabetics or IR interventions with beneficial effects against cognitive impairment and Alzheimer’s disease carry promising future application potentials.

Chronic kidney disease and IR

Chronic kidney disease (CKD) involves a gradual loss of kidney function and inability to filter blood496,497 and is a major risk factor for end-stage kidney failure (ESKF) and CVDs.498,499 And the inflammatory and glycometabolic abnormalities that closely related to IR are common features in CKD and CVD, which explain the strong relationship between them.500 In the last decades, researchers have showed that IR is an early metabolic alteration in CKD, because IR plays a primary role in metabolic syndromes characterized by abdominal obesity, high fasting glucose levels, hypertiglycemia, depressed serum HDL-C, and high blood pressure, that are commonly observed in CKD patients.401–403 Furthermore, CKD patients demonstrate systemic inflammation and elevated levels of pro-inflammatory cytokines like C-reactive protein (CRP), TNF-α, IL-6 and IL-1β.504,505 In particular, reduced renal excretion leads to abnormal plasma adipokines levels including leptin and adiponectin in CKD patients.506 Leptin may also be considered as a uremia toxin through proinflammatory effects,507,508 while adiponectin mediates insulin-sensitizing and anti-inflammatory responses.509,510 Indeed, an accumulation of leptin is larger than adiponectin in CKD, and this abnormal ratio may further promote IR and metabolic disorders.512 Despite these above factors, evidences persist that endothelial dysfunction, oxidative stress, and vitamin D deficiency are important in the glucose intolerance pathogenesis and IR in patients with CKD.413–415 Thus, newly developed methods for improving IR could lead to potential strategies for preventing excess mortality of CKD patients.

Cancer and IR

Numerous recent epidemiological studies have suggested that IR increases the risks for different cancers including colon, liver, pancreas, breast, endometrium, thyroid and gastric cancer.416–418 Diverse cellular and molecular mechanisms are involved in the relationship between IR and cancer. Further, a growing body of evidence suggests that increased insulin, in addition to IGF1 and IGF2 levels critically influence tumor initiation and progression in IR patients.419 Specifically, the three ligands (insulin, IGF1, and IGF2) binds to the receptors (IGF-IR and INSR) and activate the insulin receptor substrates. This in turn, first activates the PI3K/Akt/mTOR, PI3K/Akt/FoxO, or Ras/MAPK/ERK-1/2 pathways that have important roles in cancer cell growth and carcinogenesis.420–422 Second, these processes inactivate GSK3β through the PI3K/Akt signaling pathway, resulting in oncogenic β-catenin signaling activation, that has been associated with cancer stemness and chemoresistance.423,424 In addition, insulin and IGF1 inhibit sex-hormone binding globulin (SHBG) synthesis, although both hormones stimulate ovarian synthesis of sex steroids that can promote cellular proliferation and inhibit apoptosis in breast epithelium and endometrium.425,426 Furthermore, the increased risk of cancer in IR patients may be due to excessive ROS production that then impairs the contribution of DNA to mutation and carcinogenesis.427,428 With the elucidation of more new molecular mechanisms of IR and cancer, the relationship of IR with different tumors will be more complicated, and novel diagnostic and therapeutic strategies may provide a new approach for preventing cancer other related diseases.

THE DIAGNOSIS AND THERAPEUTIC STRATEGY OF IR

Diagnosis methods of IR

As we all know, IR is related to several metabolic abnormalities including obesity, glucose tolerance, dyslipidemia, type 2 diabetes and other metabolic syndrome.429,430 Several methods are used to measure blood insulin levels that primarily include glucose tolerance tests (GTTS), insulin tolerance tests (ITTs), hyperinsulinemic-euglycemic clamp (HEC), continuous infusion of glucose with model assessment (CIGMA), the minimal model technique (MMT), insulin suppression test (IST), and insulin release tests (IRTS) (Fig. 5), and their differences are the sensitivity, limitation, and complexity of technical procedures.431,432 Glucose tolerance test (GTT) is given to determine how quickly exogenous glucose delivered via oral, intraperitoneal, or intravenous administration is cleared from the blood.433 The GTT method is used to diagnose diabetes mellitus including T1DM, T2DM and GDM.434 The Insulin Tolerance Test (ITT) is designed to examine the systemic sensitivity of insulin receptors by measuring blood glucose levels changes before and after intravenous insulin administration.435 This method is used to assess the insulin-sensitizing efficacy of test compounds and pharmacological agents that can modify insulin sensitivity.436 However, ITT often induces adequate hypoglycemia, severe hypokalaemia, it may as the systemic counter regulatory responses following the intravenous insulin.436,437 Despite these limitations, GTT and ITT are the most widely tests for assessing insulin sensitivity, largely because they are inexpensive and easy to perform.438 The HEC has been considered as the gold-standard method to assess insulin sensitivity in vivo. Actually, IR precedes the occurrence of T2DM, so how to increase the accurate assessment of insulin sensitivity is very important to predict the risk and evaluate the management of impaired insulin sensitivity and metabolic syndrome in research and clinical practice.

As the same time, some other evaluation indices have been developed and tested the insulin sensitivity/resistance. HOMA2 (updated HOMA model which took account of variations in hepatic and peripheral glucose resistance), homeostatic Model Assessment for IR (HOMA-IR), the oral glucose insulin sensitivity index (OGSI), fasting Insulin (FINS), and fasting plasma glucose (FPG) based on fasting glucose and insulin levels439–443 are widely utilized IR measurements in clinical research. Other indices based on fasting insulin include the glucose to insulin ratio (GIR), the quantitative insulin sensitivity check index (QUICKI),444–446 triglycerides (McAuley Index) alone or in accordance with HDL cholesterol (HDL-C),447 whole-body insulin sensitivity index (WBISI), Matsuda Index to evaluate whole body physiological insulin sensitivity by the above methods. Indeed, the early symptoms of IR in different individuals are not obvious, and the relative symptoms are very complex, combining with screening indicators may provide more precise diagnosis for IR in the general population.

Therapeutic strategy of IR

Clinical approved treatment to IR. No medications exist currently that are specifically approved to treat IR, but IR management419,448,449 is possible through lifestyle changes like dietary, increased exercise, and disease prevention in addition to alternative medications (Fig. 6). Among these treatments, lifestyle changes should be the main focus for IR treatment, with nutritional intervention to decrease calories, avoidance of carbohydrates, and focusing on aliments with low glycemic index (including vegetables, fruits, whole-grain products, nuts, lean meats or beans) to provide higher fiber, vitamins, healthy fats and protein are particularly helpful for people trying to improve insulin sensitivity.450–452 A healthy diet and regular physical exercise including approximately 30 minutes of exercise at least five days a week leads to activation of muscle cells that increase AMPK activity, thereby inactivating TCB1D1 and promoting GLUT4 translocation to cellular membrane, in addition to increasing glucose uptake that increases insulin reactivity.453,454 Moreover, losing just 5%–7% of body weight can prevent or delay 60% of diabetes and ameliorate insulin sensitivity in obese and
Fig. 5 Ex vivo diagnosis methods for insulin resistance

Fig. 6 Therapeutic strategy of insulin resistance
overweight individuals. Some specific pharmacological medications have been used as preventives in type 2 diabetes by improving insulin sensitivity, primarily including Biguanides, Thiazolidinediones and GLP-1 receptor agonists, etc. (Table 1). Metformin is a first-line medication and the most widely-prescribed insulin-sensitizing agent in T2DM and PCOS patients. Metformin mediates improved insulin sensitivity by increasing insulin receptor tyrosine kinase activity, enhancing glycogen synthesis, and increasing the recruitment and activity of the glucose transporter GLUT4. Metformin also promotes re-esterification of free fatty acids and inhibits lipolysis, which may then indirectly increase insulin sensitivity by reducing lipotoxicity in adipose tissues. In addition to metformin, other targeted drugs exist for T2DM treatment and improving insulin sensitivity. For example, (1) Glucagon-like peptide 1 (GLP1) is an intestinal hormone that can enhance insulin secretion in a glucosedependent manner by activating the GLP-1 receptor (GLP-1R) that is highly expressed on islet β cells. These GLP-1 receptor agonists can suppress the inflammatory response of macrophages, thereby inhibiting IR. (2) Dipeptidyl peptidase-4 (DPP-4) also referred as the T-cell antigen CD26 can degrade GLP-1. DPP is a local mediator of inflammation and IR in adipose and hepatic tissue that interacts with the integral membrane protein, caveolin-1, then impairing the activation of down-stream AKT signaling.

Table 1. Clinical medication for improving insulin resistance

| Type              | Listed drugs                  | Mechanism                                                                 |
|-------------------|-------------------------------|---------------------------------------------------------------------------|
| Biguanides        | Metformin                     | The exact mechanism of metformin is still unclear and may be related to increased insulin receptor tyrosine kinase activity, enhanced glycogen synthesis, and recruitment of the GLUT4 glucose transporter. |
| Thiazolidinediones| Pioglitazone, Rosiglitazone   | It mainly activates peroxisome proliferator-activated receptor γ (PPAR-γ) to enhance the sensitivity of adipose muscle and liver to insulin. |
| GLP-1 receptor agonists | Liraglutide, Exenatide, Semaglutide, Dulaglutide | GLP1 receptor agonists (GLP-1RAs) can affect IR by increasing the expression of glucose transporters in insulin-dependent tissues, reducing inflammation and oxidative stress, and regulating lipid metabolism. |
| DPP-4 inhibitors  | Saxagliptin, Vildagliptin, Alogliptin, Linagliptin, Glemiglipin, Teneligliptin, Trelagliptin | It can decrease the degradation of GLP-1 by inhibiting the activity of DPP4, thereby exerting a role in the treatment of type 2 diabetes. |
| Sulfonylureas      | Glimepiride                  | It promotes insulin receptor activation, thereby increasing the amount of glucose transporters, which in turn increases insulin sensitivity and improves insulin resistance. |
| PPAR full agonists | Chiglitazar Sodium           | Chiglitazar Sodium is a peroxisome proliferator-activated receptor (PPAR) full agonist that simultaneously activates three subtypes of PPAR receptors (α, γ, and δ). It can induce the expression of downstream target genes related to insulin sensitivity, fatty acid oxidation, energy conversion, and lipid transport, and inhibit the phosphorylation of PPARα receptors associated with insulin resistance. |

Clinical trials for insulin sensitivity management. In clinical research, scientists and physicians have explored different strategies to prevent and treat diabetes mellitus and IR. We have searched the complete clinical trials (https://clinicaltrials.gov) to reduce IR and summarized them mainly include: (1) Diet intervention, such as Low-fat vegetarian Food, high-protein food, calorie restriction, vitamin D supplementation to reduce the IR in human obesity. (2) Pharmacological Intervention, such as BFKB84884A, the anti-flg1/KLB agonist antibody mimics the effect of FGF21, and causes short-term weight loss and increases insulin sensitivity. Several studies have also demonstrated that chromium picolinate administration lowers glucose and insulin levels in patients with type 2 diabetes; Salsalate inhibits IKK/NF-kB and may improve insulin sensitivity. Besides the above drugs, structural and functional dysbiosis of intestinal microbiome are induced in obese rodents and they may cause IR and systemic inflammation. Thus, sybiotic therapy on intestinal microbiota has been developed as a new treatment strategy in clinical study (NCT04642482). We present some clinical trials of IR intervention in Table 2. Over the past years, our knowledge of the pathogenesis of IR and T2DM has improved, the development of new treatments of IR and metabolic syndrome have gained certain success, while the complexity of IR and the presence of multiple feedback loops make a challenge to the specific intervention.

Preclclinical studies for IR intervention. In recent years, accumulating preclinical studies on the intervention of IR have been reported, which have important reference significance for the development of new drugs. We present the related studies on IR reported in recent years in Table 3, including animal models,
| Conditions                                      | Starting time | Phase       | Interventions                  | Treatment schedule                                                                 | Outcome measures                                                                 | NCT Number     |
|------------------------------------------------|---------------|-------------|--------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------|
| HIV Related Insulin Resistance| 2013          | Not Applicable | Drug: Tauroursodeoxycholic acid | The intervention group will receive 1.75 g of tauroursodeoxycholic acid daily for 30 days. | Glucose Uptake, Body Composition, Liver Fat, Liver Function Tests                | NCT01877551  |
| Protease Inhibitor Related Insulin Resistance| Endoplasmic Reticulum Stress | 2013          | Drug: Tauroursodeoxycholic acid |                                                                                      |                                                                                  |                |
| Metabolic Syndrome X | 2013          | Phase 3      | Drug: Ezetimibe               | Ezetimibe 10 mg/d for 12 weeks                                                       | Change in Intestinal mRNA Expression Levels of LDL Receptor, Change in Intestinal mRNA Expression Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA | NCT01849068 |
| Type 2 Diabetes Mellitus | 2015          | Phase 4      | Drug: Dapagliflozin           | Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks                              | Adjusted Change from Baseline in Skeletal Muscle Insulin-stimulated Glucose Uptake, Adjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake, Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8 | NCT02426541 |
| Diabetes| Metabolic Syndrome| Insulin Resistance | 2013          | Drug: Pegvisomant               | Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study. | Insulin Sensitivity, Lipolysis                                                  | NCT02023918  |
| Insulin Resistance| Obesity| Sedentary Lifestyle | 2013          | Behavioral: Exercise training | Study participants in the intervention arm of the study will be asked to exercise on 3 days per week for 48 weeks. | Change From Baseline in Volume of Exercise (Total Time) [Insulin Resistance], Exercise Fitness [Body Composition] | NCT01848353  |
| Diabetes Mellitus, Type 2| Skeletal Muscle Insulin Sensitivity | 2017          | Drug: Dapagliflozin           | Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days         | Corrected Glucose Disposal Rate (cGDR), Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment | NCT03338855  |
| Glucose Intolerance | 2015          | Not Applicable | Dietary Supplement: Artemisia dracunculus | Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days | Postprandial Glucose Levels, Fasting Glucose Levels, Glycosylated Hemoglobin, First Phase of Insulin Secretion, Total Insulin Secretion, Insulin Sensitivity | NCT02330341  |
| Diabetes Mellitus, Type 2 | 2018          | Not Applicable | Behavioral: SLEEP-Extend intervention | The subjects extended their sleep time by at least 1 hour but not more than 2 hours for 4 weeks. | Homeostatic Model Assessment for IR (HOMA-IR) Scores | NCT03616171  |
| Metabolic Syndrome | 2014          | Phase 4      | Drug: Sildenafil citrate      | Subjects took Sildenafil citrate 25 mg three times a day for three months.          | Insulin-stimulated AKT Phosphorylation                                      | NCT02129725  |
| Obesity Fatty Liver, Nonalcoholic | 2014          | Not Applicable | Drug: pitavastatin            | Pitavastatin 4 mg daily by mouth for 6 months                                       | Insulin-stimulated Glucose Uptake, Liver Fat, Alanine Aminotransferase, Aspartate Aminotransferase, Hepatic Insulin Sensitivity, Hemoglobin A1c, Quantitative Insulin Sensitivity Check Index | NCT02290106  |
| Diabetes Mellitus Type 2 | 2015          | Phase 2      | Drug: Momordica charantia     | Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days | Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days, Insulin Sensitivity (Matsuda Index) After 90 Days | NCT02397447  |
| Intervention and L-D-ISOPROT | Model statement | Method statement | Results | Reference |
|----------------------------|-----------------|-----------------|---------|-----------|
| Propranolol and L-D-ISOPROT | Swiss albino mice of high fructose and high fat diet (HFrHFD) model | The mice were injected with propranolol (30 mg/kg/d, i.p.) and low-dose isoproterenol (5 mg/kg/day, i.p.) for 4 weeks after the 13th week of HFrHFD feeding. | Propranolol and L-d-isopropionic acid can reduce IR of HFrHFD mice by up-regulating β-inhibin 2 signaling activity. | 505 |
| Sarsasapogenin (ZGY) | High-fat diet (HFD) C57BL/6 J mice; LPS-induced acute adipose tissue inflammation model | ZGY treatment (80 mg/kg/d, i.p. lasting for 18 days) can significantly inhibit the acute adipose tissue inflammation of LPS-treated mice. In obese mice fed with high-fat diet, taking ZGY orally (80 mg/kg/d for 6 weeks) can reduce the infiltration of macrophages, improve IR and reduce the inflammation of adipose tissue. | ZGY can improve IR and reduce fat inflammation in HFD mice, which may be related to the inhibition of IKK/NF-κB and JNK inflammatory signaling pathway. | 506 |
| PPARY Dual Agonist: Propane-2-sulfonic acid octadec-9-yl-amide (N15) | High-fat diet and streptozotocin (STZ)-induced diabetic mice | The mice were received single daily oral treatment with N15 (50 or 100 mg/kg, respectively) for 6 weeks. | The antiIR effect of N15 may be depended on PPARY pathway. | 507 |
| Valdecoxib (VAL) | HFD-fed mice | HFD - fed mice were orally administered VAL (5 mg/kg, once every 2 days) for 8 weeks. | VAL can inhibit inflammation and endoplasmic reticulum stress through AMPK-regulated HSPB1 pathway, thus improving skeletal muscle IR under hyperlipidemia. | 508 |
| D-chiro-Inositol (DCI) | HFD-fed mice | HFD-fed mice were intragastrically administered with 50 mg of DCI/kg of body weight (bw)/day for 8 weeks. | DCI decreased the hepatic glucose output and the expression levels of PEPCK and G6Pase through PKC ε-IRS/PI3K/AKT signaling pathway in insulin-resistant mice. | 509 |
| Sitagliptin | HFD-fed SD rat | Rats were given Sitagliptin (100 mg/kg/d) by gavage for 8 consecutive days. | Sitagliptin can significantly inhibit lipid accumulation in blood and liver of rats and improve insulin resistance. | 510 |
| Muscular resistance, hypertrophy and strength training | HFD-fed Swiss mice | Weight-bearing stair climbing training/Muscle resistance exercise; hypertrophy training and strength training. | Muscle resistance training program can reduce weight, obesity index, adipocyte area and low-grade chronic inflammation, and improve insulin resistance. | 511 |
| Sodium-glucose cotransporter (SGLT) 2 inhibitor: empagliflozin | HFD induced obese mice. | HFD with 0.003% empagliflozin (3 mg/kg bodyweight). And HFD with 0.01% empagliflozin (10 mg/kg bodyweight). | SGLT2 inhibitor empagliflozin enhances fat utilization and browning by M2 or replacing macrophages activation, and reduces obesity-induced inflammation and insulin resistance. | 512 |
| Heat shock protein (HSP) 70 | HFD-fed C57BL/6 mice | Mice were administered intranasally under isoflurane anesthesia, 10 μl (10 and 40 μl) of the appropriate solution was injected into one nostril, and the mice were supine for 1–2 min, three times a week for 26 days. | 4μg HSP70 significantly improved insulin sensitivity, and 10 μg HSP70 showed a trend of improvement. | 513 |
| Insulin and exenatide | Male Tg2576 mice | Daily treatment of 0.43 × 10^{-7} IU NovoRapid insulin + 0.075 μg exenatide + 5 μg BSA per mouse was used. The treatment was given every 2 days for 8 months. | Compared with the control mice, the expression of insulin receptor cascade related genes in Aβ1-42 mice treated with insulin and exenatide was normalized. | 514 |
| GLP-1 receptor agonists: exendin-4 | Senescence-accelerated mouse (SAMP8) | A proper amount of exendin-4 and L-form of penetratin were respectively dissolved in PBS solution containing 0.001% methylcellulose (MC), and an equal amount of peptide drug and osmotic solution were gently mixed. The mice were injected with sodium pentobarbital intraperitoneally and then with exendin-4 and L-penetratin intranasally. | After intranasal administration with L-form of penetratin, the distribution of exendin-4 in the whole brain increased significantly. Through intranasal injection of L-form of penetratin, the delivery of exendin-4 and insulin to the brain may contribute to insulin signal transduction in hippocampus. | 515 |
| Lactobacillus reuteri strain | HFD-fed mice | The mice were gavaged daily with 10^6 CFU of L. reuteri CNCM I-5022 for 12 weeks. | Lactobacillus reuteri improved HOMA-IR and glucose clearance and exhibited better insulin sensitivity in HFD-fed mice. | 516 |
| Sterilized bifidobacteria | HFD-fed mice | Mice were orally administered with bifidobacteria (200 mg/kg, 400 mg/kg) daily for 4 weeks. | Oral glucose tolerance and IR test showed that Bifidobacterium sterilization could improve glucose tolerance and reduce insulin resistance. | 517 |
| Exercise training combined with Bifidobacterium longum OLP-01 | Male C57BL/6 J db/db mice | The mice were administrally at a dosage of 1.03 g per kg per day (1.03 × 10^5 CFU per kg per day) using a stomach tube. The mice were supplemented with strength training. | Exercise and OLP-01 treatment show that they can reduce blood sugar, increase insulin sensitivity, reduce body fat, improve physical activity and protect liver injury, but have no adverse effects. | 518 |
treatment methods and results. Pre-clinical IR intervention mainly includes drug intervention, probiotic therapy and exercise supplement. Drug therapy to improve IR is the main research direction at present. Researchers found that Valdecoxib (VAL) can inhibit inflammation and endoplasmic reticulum (ER) stress through AMPK-regulated HSPB1 pathway, thus improving skeletal muscle IR under hyperlipidemia.\textsuperscript{502} The insulin signal described above has a key role in AD pathogenesis. The researchers found that probiotics can effectively alleviate IR. Regular exercise is an alternative intervention by Lactobacillus reuteri strain could effectively alleviate IR. The above results show that drug intervention, probiotic therapy and exercise play an important role in treating IR. However, clinical data are still needed.

ACKNOWLEDGEMENTS
This work was supported by NANJING ANJI BIOTECHNOLOGY Co. Ltd, the Project Program of State Key Laboratory of Natural Medicines (SKLMZZ2020228) and National Natural Science Foundation of China (82103118). Figure 3 was created with BioRender.com and exported under a paid subscription.

AUTHOR CONTRIBUTIONS
M.W.L, W.X.C, and Y.W. wrote the article and researched the data for the article. H.M.X, S.S, and W.W.X reviewed and revised the article. All authors contributed to reviewing and editing the manuscript before submission.

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

REFERENCES
1. Banting, F. G. & Best, C. H. The internal secretion of the pancreas. 1922. Indian J. Med. Res. 125, 251–266 (2007).
2. SANGER, F. & THOMPSON, E. O. The amino-acid sequence in the glycyl chain of insulin. Biochem J. 53, 353–366 (1953).
3. SANGER, F. & THOMPSON, E. O. The amino-acid sequence in the glycyl chain of crystalline bovine insulin. Proc. Natl Acad. Sci. USA 11, 353 (1953).
4. Kung, Y. T., Du, Y. C., Huang, W. T., Chen, C. C. & Ke, L. T. Total synthesis of crystalline bovine insulin. Sci. Sin. 14, 1710–1716 (1965).
5. Goeddel, D. V. et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76, 106–110 (1979).
6. Vecchio, I., Tornali, C., Bragazzi, N. L. & Martini, M. The discovery of insulin: an important milestone in the history of medicine. Front Endocrinol. 9, 613 (2018).
7. Cheatham, B. & Kahn, C. R. Insulin action and the insulin signaling network. Endocr. Rev. 16, 117–142 (1995).
8. Root, H. F. Insulin resistance and bronze diabetes. N. Engl. J. Med. 201, 201–206 (1929).
9. Laakso, M. & Kuusisto, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10, 293–302 (2014).

Trends in insulin resistance: insights into mechanisms and therapeutic... Li et al.
Diabetes 57. Kahn, B. B. Glucose transport: pivotal step in insulin action.

55. Kruszynska, Y. T. et al. Fatty acid-induced insulin resistance: decreased muscle

70. Zidon, T. M. et al. Effects of ERα and-3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in

47. Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C. & Cantley, L. C. Phos-

63. Ryder, J. W. et al. Use of a novel impermeable biotinylated photolabeling

62. Etgen, G. J. Jr et al. Exercise training reverses insulin resistance in muscle by

49. Czech, M. P. & Corvera, S. Signaling mechanisms that regulate glucose transport.

25. Diabetes Care 25, 1596–1607 (2005).

61. Chatham, B. et al. Phosphatidylinositol-3 kinase activation is required for insulin stimulation of p70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 14, 4902–4911 (1994).

61. Chatham, B. et al. Phosphatidylinositol-3 kinase activation is required for insulin stimulation of p70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 14, 4902–4911 (1994).

57. Kahn, B. B. Glucose transport: pivotal step in insulin action.

44. Davis, R., Aguirre, V., Uchida, T., Yenush, L. & White, M. F. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J. Biol. Chem. 275, 9047–9054 (2000).

45. Carvalho-Filho, M. A. et al. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 54, 959–967 (2005).

46. Taniuchi, G. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96 (2006).

48. Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C. & Cantley, L. C. Phos-

24. Cherrington, A. D. et al. Physiologic role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol. Endocrinol. 11, 1881–1890 (1997).

50. Luo, J. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab. 3, 355–366 (2006).

51. Cong, L. N. et al. Physiological role of Akt in insulin-stimulated translocation of GLUT4 and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell Biol. 25, 1596–1607 (2005).

54. Brozinick, J. T., Roberts, B. R. & Dohm, G. L. Defective signaling through Akt-2

64. Garvey, W. T., Maianu, L., Zhu, J. H., Hancock, J. A. & Golichowski, A. M. Multiple

67. Tramunt, B. et al. Sex differences in metabolic regulation and diabetes sus-

65. Ehtisham, S., Crabtree, N., Clark, P., Shaw, N. & Barrett, T. Ethnic differences in

90. Oosterman, J. E., Wopereis, S. & Kalsbeek, A. The circadian clock, shift work, and

94. Sung, C. C., Liao, M. T., Lu, K. C. & Wu, C. C. Role of vitamin D in insulin resistance.

91. McAuley, K. A. et al. Intensive lifestyle changes are necessary to improve

92. McDonald, J. et al. Dietary weight loss and exercise effects on insulin resistance in

65. Chatham, B. et al. Phosphatidylinositol-3 kinase activation is required for insulin stimulation of p70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 14, 4902–4911 (1994).

66. Chen, S., Wasserman, D. H., MacKintosh, C. & Sakamoto, K. Mice with AS160/

67. Tambrt, B. et al. Sex differences in metabolic regulation and diabetes sus-

68. Greenhill, C. Sex differences in insulin resistance. Nat. Rev. Endocrinol. 14, 65–65 (2018).

69. Qu, J. et al. Estradiol protects proopiomelanocortin neurons against insulin resistance. Endocrinology 159, 647–664 (2018).

70. Zidon, T. M. et al. Effects of ERβ and ERα on OXV-induced changes in adiposity and insulin resistance. J. Endocrinol. 245, 165–178 (2020).

71. Ikeda, K., Horie-Inoue, K. & Inoue, S. Functions of estrogen and estrogen receptor signaling on skeletal muscle. J. Steroid Biochem Mol. Biol. 191, 105375 (2020).

72. Gerds, T. & Regitz-Zagrosek, V. Sex differences in cardioembolic disorders. Nat. Med. 25, 1657–1666 (2019).

68. Greenhill, C. Sex differences in insulin resistance. Nat. Rev. Endocrinol. 14, 65–65 (2018).

69. Qu, J. et al. Estradiol protects proopiomelanocortin neurons against insulin resistance. Endocrinology 159, 647–664 (2018).

70. Zidon, T. M. et al. Effects of ERβ and ERα on OXV-induced changes in adiposity and insulin resistance. J. Endocrinol. 245, 165–178 (2020).

71. Ikeda, K., Horie-Inoue, K. & Inoue, S. Functions of estrogen and estrogen receptor signaling on skeletal muscle. J. Steroid Biochem Mol. Biol. 191, 105375 (2020).

72. Gerds, T. & Regitz-Zagrosek, V. Sex differences in cardioembolic disorders. Nat. Med. 25, 1657–1666 (2019).
Trends in insulin resistance: insights into mechanisms and therapeutic... Li et al.
20

163. Boden, G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes* 46, 3–10 (1997).

164. Rothman, D. L. et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. *Proc Natl Acad. Sci. USA* 92, 983–987 (1995).

165. Cline, G. W. et al. Upreregulation of myocellular DGAT1 augments triglyceride synthesis in type 2 diabetes. *N. Engl. J. Med.* 341, 240–246 (1999).

166. Dresner, A. et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *J. Clin Invest* 103, 253–259 (1999).

167. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J. Biol. Chem.* 277, 50239–50236 (2002).

168. Eroon, D. M. & Shulman, G. I. Diacylglycerol-mediated insulin resistance. *Nat. Med.* 16, 400–402 (2010).

169. Kim, J. K. et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. *J. Clin Invest* 114, 823–827 (2004).

170. Blachnio-Zabielska, A. U., Chacinska, M., Vendelbo, M. H. & Zabielski, P. The role of peroxisome proliferator-activated receptor gamma in skeletal muscle and protects against fat-induced insulin resistance. *J. Clin Invest* 117, 1679–1689 (2007).

171. Yen, C. L., Monetti, M., Burri, B. J. & Farese, R. V. Jr. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters. *J. Lipid Res.* 46, 1502–1511 (2005).

172. Timmers, S., Schrauwen, P. & de Vogel, J. Muscular diacylglycerol metabolism and insulin resistance. *Physiol. Behav.* 94, 242–251 (2008).

173. Liu, L. et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. *Proc. Natl Acad. Sci. USA* 99, 13330–13335 (2002).

174. Schubert, K. M., Scheid, M. P. & Duronio, V. Ceramide inhibits protein kinase B/ Akt by promoting dephosphorylation of serine 473. *J. Biol. Chem.* 275, 13330–13335 (2000).

175. Nagai, Y. et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. *Cell Metab.* 9, 252–264 (2009).

176. Yu, C. et al. The role of the PPARG (Pro12Ala) common genetic variant on type 2 diabetes susceptibility. *J. Biol. Chem.* 277, 50239–50236 (2002).

177. Cline, G. W. et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. *N. Engl. J. Med.* 341, 99–106 (2004).

178. Friedman, J. S. et al. Cross talk between adipocytes and muscle: obesity-induced increases in skeletal muscle lipolysis and lipid-induced resistance to insulin-stimulated glucose transport. *Diabetes* 57, 5023–5029 (2008).

179. Zeng, Q. et al. Association Between Insulin-like Growth Factor-1 rs35767 Poly-morphism and Type 2 Diabetes Mellitus Susceptibility: A Meta-Analysis. *Front Genet* 12, 774489 (2021).

180. Knowles, J. W. et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. *J. Clin Invest* 126, 403 (2016).

181. Hashemian, L., Sarhangi, N., Afshari, M., Aghaei Meybodi, H. R. & Hasananzad, M. The role of the PPARγ (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk. *J. Diabetes Metab. Disord.* 20, 1385–1390 (2021).

182. Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. *Nat. Rev. Genet* 11, 446–450 (2010).

183. Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. *Nature* 570, 71–76 (2019).

184. Winkler, A. et al. Genetic variants in inflammation and insulin resistance. *Ann. Med.* 48, 497–499 (2016).

185. Liu, J. et al. Epigenetic germ-line inheritance of type 2 diabetes susceptibility. *Cell Metab.* 29, 1028–1044 (2019).

186. Ahmed, S. et al. The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. *Clin. Epigenetics* 12, 1–23 (2020).

187. Ling, C. et al. Epigenetic regulation of insulin action and secretion-role in the pathogenesis of type 2 diabetes. *Diabetes* 61, 542–546 (2012).

188. Zhou, Z., Sun, B., Li, X. & Zhu, C. DNA methylation landscapes in the pathogenesis of type 2 diabetes mellitus. *DNA methylation Landsc. pathways type 2 diabetes Mellit.* 15, 1–8 (2018).

189. Liu, J. et al. An integrative cross-omics analysis of DNA methylation sites of glucose and insulin homeostasis. *Nat. Commun.* 10, 1–11 (2019).

190. Gu, T. et al. DNA methylation analysis of the insulin-like growth factor-1 (IGF1) gene in Swedish men with normal glucose tolerance and type 2 diabetes. *J. Diabetes Metab.* 5, 2 (2014).

191. Wittenbecher, C. et al. Insulin-like growth factor binding protein 2 (IGFBP-2) and the risk of developing type 2 diabetes. *Diabetes* 68, 188–197 (2019).

192. Haywood, N. J., Slater, T. A., Matthews, C. J. & Wheatcroft, S. B. The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes. *Mol. Metab.* 19, 86–96 (2019).

193. Crueiras, A. B. et al. Genome-wide DNA methylation pattern in visceral adipose tissue differentiates insulin-resistant from insulin-sensitive obese subjects. *Transl. Res.* 178, 13–24 (2018).

194. Ma, X. & Kang, S. Functional implications of DNA methylation in adipose biology. *Diabetes* 68, 871–879 (2019).

195. Gao, H. et al. Long non-coding RNAs associated with metabolic traits in human whole adipose tissue. *PLoS One* 8, e56088 (2013).

196. Brown, A. E. & Walker, M. Genetics of Insulin Resistance and the Metabolic Syndrome. *Curr. Cardiol. Rep.* 18, 75 (2016).

197. Chen, Z. et al. Functional Screening of Candidate Causal Genes for insulin Resistance in Human Preadipocytes and Adipocytes. *Circ. Res.* 126, 330–346 (2020).

198. Shakhanna, A. et al. Association of polymorphism genes LPL, ADRB2, AGT and AGTR1 with risk of hyperinsulinism and insulin resistance in the Kazakh population. *Biomedi. Rep.* 13, 35 (2020).

199. Henkin, L. et al. Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. *Ann. Epidemiol.* 13, 211–217 (2003).

200. Parks, B. W. et al. Genetic architecture of insulin resistance in the mouse. *Cell Metab.* 21, 334–347 (2015).

201. Xue, A. et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat. Commun.* 9, 2941 (2018).

202. Yousef, A. A. et al. IRS-1 genetic polymorphism (rs2963 G > A) in type 2 diabetes mellitus patients associated with insulin resistance. *Appl Clin Genet* 11, 99–106 (2018).

203. Hashemian, L., Sarhangi, N., Afshari, M., Aghaei Meybodi, H. R. & Hasananzad, M. The role of the PPARγ (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk. *J. Diabetes Metab. Disord.* 20, 1385–1390 (2021).
284. Rinninella, E. et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7, 14 (2019).
285. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
286. Shi, Z. Gut microbiota: An important link between western diet and chronic diseases. Nutrients 11, 2287 (2019).
287. Quirroga, R. et al. Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children. Exp. Mol. Med. 52, 1048–1061 (2020).
288. Claus, M., Gérard, P., Mosca, A. & Leclerc, M. Interplay between exercise and gut microbiome in the context of human health and performance. Front. Nutr. 8, 637010 (2021).
289. Matenckh, B. A., Mandahane, P. J. & Kozyszyk, A. L. Sleep, circadian rhythm, and gut microbiota. Sleep. Med. Rev. 53, 101340 (2020).
290. Stenvers, D. J. Circadian clocks and insulin resistance. Nat. Rev. Endocrinol. 15, 75–89 (2019).
291. Ramírez, J. Antibiotics as major disruptors of gut microbiota. Front. Cell. Infect. Microbiol. 10, 572912 (2020).
292. Awany, D. Host and microbiome genome-wide association studies: current state and challenges. Front Genet. 9, 637 (2019).
293. Cahana, I. & Iqai, F. A. Impact of host genetics on gut microbiome: Take-home lessons from human and mouse studies. Anim. Model Exp. Med. 3, 229–236 (2020).
294. Lee, C. J., Sears, C. L. & Maruthur, N. Gut microbiome and its role in obesity and insulin resistance. Ann. N. Y Acad. Sci. 1461, 37–52 (2020).
295. Gérard, C. et al. Impact of gut microbiota on host glycemic control. Front Endocrinol. 10, 29 (2019).
296. Del Chierico, F. et al. Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity: a pilot study. Acta Diabetol. 58, 1009–1022 (2021).
297. Wu, H. et al. The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Cell Metab. 32, 379–390 (2020).
298. Andoh, A. et al. Comparison of the gut microbial community between obese and lean peoples using 16 S gene sequencing in a Japanese population. J. Clin. Biochem. Nutr. 59, 65–70 (2016).
299. Agus, A., Clément, K. & Sokol, H. T. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 70, 1174–1182 (2021).
300. Martin, A. M., Sun, E. W., Rogers, G. B. & Keating, D. J. The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. Front Physiol. 10, 428 (2019).
301. Scheithauer, T. P. et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 11, 571731 (2020).
302. de Groot, P. et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut 69, 502–512 (2020).
303. Salles, B. I. M., Clöff, D. & Ferreira, S. R. G. Probiotics supplementation and insulin resistance: a systematic review. Diabetol. Metab. Synd. 12, 1–24 (2020).
304. Johnson, J. D. On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes. Diabetologia 64, 2138–2146 (2021).
305. Wilcox, G. Insulin and insulin resistance. Clin. Biochem. Rev. 26, 19–39 (2005).
306. Kashyap, S. R. & DeFronzo, R. A. The insulin resistance syndrome: physiological considerations. Diab. Vasc. Dis. Res. 4, 13–19 (2007).
307. Reaven, G. M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 47, 201–210 (2005).
308. Gluvic, Z. et al. Link between metabolic syndrome and insulin resistance. Curr. Vasc. Pharm. 15, 30–39 (2017).
309. Ahmed, A., Wong, R. J. & Harrison, S. A. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin. Gastroenterol. Hepatol. 13, 2062–2070 (2015).
310. Chen, Z., Yu, R., Xiong, Y., Du, F. & Zhu, S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 16, 1–9 (2017).
311. Leonardi, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 47, 181–190 (2015).
312. Gross, B., Pawlak, M., Lefebvre, P. & Staels, B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat. Rev. Endocrinol. 13, 36–46 (2017).
313. Gao, B. & Tsuikamoto, H. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology 150, 1704–1709 (2016).
314. Neuschwander-Tetri, B. A. Hepatic lipotoxicity and the pathogenesis of non-alcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52, 774–788 (2010).
315. Perota, S. et al. Pathophysiology of non alcoholic fatty liver disease. Int. J. Mol. Sci. 17, 2082 (2016).
normal and polycystic ovary syndrome theca cells. J. Clin. Endocrinol. Metab. 85, 2304–2311 (2000).

347. Diamantid-Kandarakis, E. & Papavasiliou, A. G. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol. Med. 12, 324–332 (2006).

348. Cardiovascular diseases (CVDs). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

349. P. Pearl-Stuttard et al. Reducing US cardiovascular disease burden and disparities through national and targeted dietary policies: a modelling study. PLoS Med 14, e1002311 (2017).

350. Viran, S. S. et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 143, e254–e743 (2021).

351. Nabel, E. G. Cardiovascular disease. N. Engl. J. Med. 349, 60–72 (2003).

352. National Center for Biotechnology Information (US). Genes and Disease (Internet), Bethesda (MD): National Center for Biotechnology Information (US), 1998.-The Heart and Blood Vessels. Available from: https://www.ncbi.nlm.nih.gov/books/NBK22227/.

353. Ormazabal, V. et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 17, 1–14 (2018).

354. Shulman, G. I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med 371, 2237–2238 (2014).

355. Janus, A., Szahidewicz-Krupska, E., Mazur, G. & Doroszko, A. Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediators Inflamm. 2016, 3634948 (2016).

356. Stančáková, A. et al. Changes in insulin sensitivity and insulin release in relation to glyceria and glucose tolerance in 6,414 Finnish men. Diabetes 58, 1212–1221 (2009).

357. Rawshani, A. et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N. Engl. J. Med. 376, 1407–1418 (2017).

358. Amer, P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab. Res Rev. 18, 55–59 (2002).

359. Van Gaal, L. F., Mertens, I. L. & Christophie, E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875–880 (2006).

360. Montani, J. P. et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J. Obes. Relat. Metab. Disord. 28, 558–565 (2004).

361. Wende, A. R. & Abel, E. D. Lipotoxicity in the heart. Biochim. Biophys. Acta 1801, 311–319 (2010).

362. Hedegård, M. et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 19, 1–11 (2020).

363. Nicholls, S. & Lundman, P. Practical Approach to Diagnosis & Management of Type 2 Diabetes and Diabetic Complications. N. Engl. J. Med. 370, E174–E183 (2019).

364. Hartge, M. M., Unger, T. & Kintscher, U. The endothelium and vascular impairment in diabetes. Nature Med 13, 223–239 (2012).

365. landreth, G., Jiang, Q., Mandrekar, S. & Heneka, M. PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5, 481–489 (2008).

366. Remels, A. H. et al. PPARγamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 297, E174–E183 (2009).

367. Miller, B. W., Willett, K. C. & Desiltes, A. R. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann. Pharmacother. 45, 1416–1424 (2011).

368. Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic Kidney Disease. Lancet 369, 1238–1252 (2017).

369. Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention (2019).

370. Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic kidney disease among nondiabetic adults. JAMA 325, 1512–1525 (2016).

371. Mirabelli, M. et al. Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Adv. Nutr. 5, 469–480 (2016).

372. Bagyinszky, E. et al. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J. Neurosci. 376, 242–254 (2017).

373. Erol, A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer’s disease. J. Alzheimers Dis. 13, 241–253 (2008).

374. Suzanne, M. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs 77, 47–65 (2017).

375. Ringheim, R. G. et al. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res Mol. Brain Res 55, 35–44 (1998).

376. Bauer, J. et al. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett. 285, 111–114 (1991).

377. U. M., Quintana, A. & Hidalgo, J. Interleukin-6, a major cytokine in the central nervous system. Int J. Biol. Sci. 8, 1254–1266 (2012).

378. Landreth, G., Jiang, Q., Mandrekar, S. & Heneka, M. PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5, 481–489 (2008).

379. Remels, A. H. et al. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 297, E174–E183 (2009).

380. Miller, B. W., Willett, K. C. & Desiltes, A. R. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann. Pharmacother. 45, 1416–1424 (2011).

381. Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic Kidney Disease. Lancet 369, 1238–1252 (2017).

382. Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention (2019).

383. Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32, 5112–5119 (1998).

384. Romagnani, P. et al. Chronic kidney disease. Nat. Rev. Dis. Prim. 3, 17088 (2017).

385. Mirabelli, M. et al. Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Adv. Nutr. 5, 469–480 (2016).

386. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).

387. Kurella, M., Lo, J. C. & Chertow, G. M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 16, 2134–2140 (2005).

388. Ryu, S. et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am. J. Kidney Dis. 53, 913 (2009).

389. Kizer, T. A. Nutrition, inflammation and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 17, 162–167 (2008).

390. Borazan, A. & Bincici, D. N. Relationship between insulin resistance and inflammation markers in hemodialysis patients. Ren. Fail. 32, 198–202 (2010).

391. Slee, A. D. Exploring metabolic dysfunction in chronic kidney disease. Nutr. Metab. (Lond.) 9, 36 (2012).

392. Ottolino, L. et al. Lepatin as a uricemic toxin interferes with uricoprotein chemo- taxis. J. Am. Soc. Nephrol. 15, 2366–2372 (2004).

393. Stenvek, P. Lepatin—a new hormone of definite interest for the nephrologist. Nephrol. Dial Transpl. 13, 1099–1101 (1998).

394. Berg, A. H., Combs, T. P., Du, X., Brownlee, M. & Scherer, P. E. The adipoocyte- secreted protein Acp30 enhances hepatic insulin action. Nat. Med. 7, 947–953 (2001).

Trends in insulin resistance: insights into mechanisms and therapeutic… Li et al.
24

410. Yamuchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both obesity and osteoporosis. Nat. Med. 7, 941–946 (2001).

411. Jia, T., Carrero, J. J., Lindholm, B. & Stenvinkel, P. The complex role of adiponectin in chronic kidney disease. Biochimie 94, 2150–2156 (2012).

412. Teta, D. Insulin resistance as a therapeutic target for chronic kidney disease. J. Ren. Nutr. 25, 226–229 (2015).

413. Nogueira, F., Tripepi, G., Cutrupi, S., Malatino, L. S. & Zoccali, C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 67, 2330–2337 (2005).

414. Thomas, S. S., Mena, S., Ortega, A. & Estrela, J. M. Oxidative stress in environmental-induced insulin resistance in chronic kidney disease. Kidney Int 88, 1233–1239 (2015).

415. Liao, M. T. et al. Insulin resistance in patients with chronic kidney disease. J. Biomed. Biotechnol. 2012, 691369 (2012).

416. Arcidiacano, B. et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp. Diabetes Res 2012, 789174 (2012).

417. Tsugane, S. & Inoue, M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 101, 1073–1079 (2010).

418. Godsland, I. F. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. (Lond.) 118, 315–332 (2009).

419. Djouge, S. et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr. Relat. Cancer 20, R1–R17 (2013).

420. Alvinio, C. L. et al. Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS One 6, e26748 (2011).

421. Tzivion, G., Dobson, M. & Ramakrishnan, G. FoxO transcription factors: Regulation by AKT and 1-4-3-3 proteins. Biochem. Biophys. Acta 1813, 1938–1945 (2011).

422. Hao, P. et al. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways. Exp. Cell Res 403, 112615 (2021).

423. Fleming, H. E. et al. Wnt signaling in the niche endorses hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2, 274–283 (2008).

424. Ashihara, E. et al. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin. Cancer Res. 15, 2731–2738 (2009).

425. Kaaks, R. & Lukanova, A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc. Nutr. Soc. 60, 91–106 (2001).

426. Hursting, S. D. & Berger, N. A. Energy balance, host-related factors, and cancer progression. J. Clin. Oncol. 28, 4058–4065 (2010).

427. Mena, S., Ortega, A. & Estrela, J. M. Oxidative stress in environmental-induced carcinogenesis. Mutat. Res. 674, 36–44 (2009).

428. Tiganis, T. Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends Pharm. Sci. 32, 82–89 (2011).

429. Roberts, C. K., Heveren, A. L. & Barnard, N. R. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr. Physiol. 3, 1–58 (2013).

430. Kahn, B. B. & Flier, J. S. Obesity and insulin resistance. J. Clin. Endocrinol. Metab. 86, 4618–4621 (2001).

431. Katz, A. et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2422–2430 (2000).

432. Chen, H., Sullivan, G. & Quon, M. J. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 54, 1914–1925 (2005).

433. Sumner, A. E., Finley, K. B., Genovese, D. J., Criqui, M. H. & Boston, R. C. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch. Intern. Med. 165, 1395–1400 (2005).

434. Thaane, T., Motala, A. A. & McKune, A. J. Lifestyle modification in the management of insulin resistance states in overweight/obesity: the role of exercise training. J. Endocrinol. Metab. Diabetes South Afr. 24, 65–69 (2019).

435. Matthaei, S., Stumvoll, M., Kellerer, M. & Häring, H. U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. 21, 585–618 (2000).

436. Boden, G., Sargrad, K., Homko, C., Mozzoli, M. & Stein, T. P. Effect of a low-carbohydrate, blood diet low in glycemic index on obesity, insulin resistance in obese patients with type 2 diabetes. Ann. Intern. Med. 142, 403–411 (2005).

437. Isharwal, S., Misra, A., Wasir, J. S. & Nigam, P. Diet & insulin resistance: a review & Asian Indian perspective. Indian J. Med. Res. 129, 485 (2009).

438. Snel, M. et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int. J. Endocrinol. 2012, 983814 (2012).

439. Hawley, J. A. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab. Res. Rev. 20, 383–393 (2004).

440. Fedewa, M. V., Gist, N. H., Evans, E. M. & Dishman, R. K. Exercise and insulin resistance in youth: a meta-analysis. Pediatrics 133, e163–e174 (2014).

441. Clamp, L. D., Hume, D. J., Lambert, E. V. & Kroff, J. Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history. Nutr. Diabetes 7, e282–e282 (2017).

442. Van der Aa, M. P. et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr. Diabetes 6, e228–e228 (2016).

443. Velazquez, E. M., Mendoza, S., Homer, T., Sosa, F. & Glueck, C. J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43, 647–654 (1994).

444. Giannarelli, R., Aragona, M., Coppelli, A. & Del Prato, S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 29, 6528–6535 (2003).

445. Ruegesger, G. N. et al. Exercise and metformin counteracted altered mitochondrial function in the insulin-resistant brain. JCI Insight, e130681 (2019).

446. Lee, J. O. et al. Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated CICRAR signaling in 3T3-L1 preadipocytes. J. Biol. Chem. 287, 44121–44129 (2012).

447. Kim, H. S. et al. Metformin reduces saturated fatty acid-induced lipid accumulation and inflammatory response by restoration of autophagic flux in endothelial cells. Sci. Rep. 10, 1–14 (2020).

448. MacDonald, P. E. et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51, S434–S442 (2002).

449. Vendrell, J. et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152, 4072–4079 (2011).

450. Oliveira, J., Lau, E., Carvalho, D. & Freitas, P. Glucagon-like peptide-1 analogues: an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. J. Med. Case Rep. 11, 1–4 (2017).

451. Tran, K. L. et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am. Health Drug Benefits 10, 178 (2017).

452. Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. (Lausanne) 10, 155 (2019).

453. Sharma, D. et al. Overview of GLP-1 antagonists: Current advancements & challenges. Biomed. Pharmacother. 108, 952–962 (2018).

454. Hansen, B. B. et al. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. J. Med. Econ. 23, 650–658 (2020).

455. Lee, Y. S. & Jun, H. S. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediterr. Inflamn. 2016, 3094642 (2016).
470. Deacon, C. F. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. (Lausanne) 10, 80 (2019).
471. Ghorpade, D. S. et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555, 673–677 (2018).
472. Trzaskalski, N. A., Fadzeyeva, E. & Mulvihill, E. E. Dipeptidyl peptidase-4 at the interface between inflammation and metabolism. Clin. Med. Insights Endocrinol. Diabetes 13, 1179551-209012972 (2020).
473. Nargis, T. & Chakrabarti, P. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB life 70, 112–119 (2018).
474. Hattori, S. Omaliprotein decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes. Diabetol. Metab. Syndr. 12, 1–7 (2020).
475. Drucker, D. J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes care 30, 1335–1343 (2007).
476. Richter, B., Bandeira-Echtler, E., Bergerhoff, K. & Lerch, C. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2008, CD006739 (2008).
477. Wilcox, C. S. Antihyperensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension 75, 894–901 (2020).
478. Brown, E., Heerspink, H. J., Cuthbertson, D. J. & Wilding, J. P. S. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398, 262–276 (2021).
479. Betelsheee, A. L., Leslie, B. R. & Taylor, S. i. Sodium-glucose cotransporter 2 inhibitors: A case study in translational research. Diabetes 68, 1109–1120 (2019).
480. McGuire, D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 6, 148–158 (2021).
481. Jurczak, M. J. et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function. Diabetes 60, 890–898 (2011).
482. Al Jobori, H. et al. Empagliflozin treatment is associated with improved β-cell function in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 1402–1407 (2018).
483. Sugli, S. et al. PPARα activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl Acad. Sci. USA 106, 22504–22509 (2009).
484. Astapova, O. & Leff, T. Adiponectin and PPARα: cooperative and interdependent actions of two key regulators of metabolism. Vitom. Horm. 90, 143–162 (2012).
485. Fuentes, E., Guzmán-Jofre, L., Moore-Carrasco, R. & Paloma, I. Role of PPARs in inflammatory processes associated with metabolic syndrome. Mol. Med. Rep. 8, 1611–1616 (2013).
486. Saltiel, A. R. & Olefsky, J. M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661–1669 (1996).
487. Amer, P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14, 137–145 (2003).
488. Goedeke, L., Perry, R. J. & Shulman, G. I. Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes. Annu Rev. Pharm. Toxicol. 59, 65–87 (2019).
489. Lewandowski, K. C., Dąbrowska, K., Brzozowska, M., Kawalec, J. & Lewirska, A. Metformin paradoxically worsens insulin resistance in SHORT syndrome. Diabetes Metab. Syndr. 11, 1–4 (2019).
490. Lakka, T. A. et al. A 2 year physical activity and dietary intervention attenuates the increase in insulin resistance in a general population of children: the PANIC study. Diabetologia 63, 2270–2281 (2020).
491. Pramono, A., Jocken, W. J., Blaak, E. E. & van Baak, M. A. The effect of vitamin D supplementation on insulin sensitivity: a systematic review and meta-analysis. Diabetes care. 43, 1659–1669 (2020).
492. Baruch, A. New antibody-mediated activation of the FGFRI/Klotho complex corrects metabolic dysfunction and alters food preference in obese humans. Proc. Natl Acad. Sci. USA 117, 28992–29000 (2020).
493. Sonoda, J., Chen, M. Z. & Baruch, A. FGFR21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig. 30, jhmbci.2017.30. issue-2/hmbci.2017-0002/hmbci.2017-0002.xhtml (2017).
494. Hua, Y., Clark, S., Ren, J. & Sreejayan, N. Molecular mechanisms of chromium in alleviating insulin resistance. J. Nutr. Biochem. 23, 313–319 (2012).
495. Dubey, P., Thakur, V. & Chattopadhyay, M. Role of minerals and trace elements in diabetes and insulin resistance. Nutrients 12, 1864 (2020).
496. Goldfine, A. B. et al. A randomized trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56, 714–723 (2013).